Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2017 | Apr. 30, 2017 | |
Document Information [Line Items] | ||
Entity Registrant Name | AMYRIS, INC. | |
Entity Central Index Key | 1,365,916 | |
Trading Symbol | amrs | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 297,086,351 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2017 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 | |
Assets | |||
Cash and cash equivalents | $ 1,297 | $ 27,150 | |
Restricted cash | 301 | 4,326 | |
Short-term investments | 1,188 | 1,374 | |
Accounts receivable, net of allowance of $478 and $478, respectively | 8,122 | 13,105 | |
Related party accounts receivable, net of allowance of $23 and $23, respectively | 416 | 872 | |
Inventories, net | 7,077 | 6,213 | |
Prepaid expenses and other current assets | 5,652 | 6,083 | |
Total current assets | 24,053 | 59,123 | |
Property, plant and equipment, net | 53,045 | 53,735 | |
Restricted Cash and Cash Equivalents, Noncurrent | 958 | 957 | |
Equity and loans in affiliates | 34 | 34 | |
Other assets | 16,794 | 15,464 | |
Goodwill and intangible assets | 560 | 560 | |
Total assets | 95,444 | 129,873 | |
Liabilities, Mezzanine Equity and Stockholders' Deficit | |||
Accounts payable | 16,453 | 15,315 | |
Deferred revenue | 3,487 | 5,288 | |
Accrued and other current liabilities | 31,806 | 29,188 | |
Capital lease obligation, current portion | 405 | 922 | |
Debt, current portion | 15,290 | 25,853 | |
Related party debt | 34,165 | 33,302 | |
Total current liabilities | 101,606 | 109,868 | |
Capital lease obligation, net of current portion | 405 | 334 | |
Long-term debt, net of current portion | 131,759 | 128,744 | |
Related party debt | 39,724 | 39,144 | |
Deferred rent, net of current portion | 8,691 | 8,906 | |
Deferred revenue, net of current portion | 6,650 | 6,650 | |
Derivative liabilities | 5,144 | 6,894 | |
Other liabilities | 7,716 | 7,841 | |
Total liabilities | 301,695 | 308,381 | |
Commitments and contingencies (Note 6) | |||
Contingently redeemable common stock (Note 8) | [1] | 5,000 | 5,000 |
Stockholders’ deficit: | |||
Preferred stock - $0.0001 par value, 5,000,000 shares authorized, none issued and outstanding | |||
Common stock - $0.0001 par value, 500,000,000 and 500,000,000 shares authorized as of March 31, 2017 and December 31, 2016, respectively; 287,973,020 and 274,108,808 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively | 28 | 27 | |
Additional paid-in capital | 1,000,174 | 990,870 | |
Accumulated other comprehensive loss | (40,581) | (40,904) | |
Accumulated deficit | (1,171,809) | (1,134,438) | |
Total Amyris, Inc. stockholders’ deficit | (212,188) | (184,445) | |
Noncontrolling interest | 937 | 937 | |
Total stockholders' deficit | (211,251) | (183,508) | |
Total liabilities, mezzanine equity and stockholders' deficit | $ 95,444 | $ 129,873 | |
[1] | See Note 8, "Significant Agreements" for details regarding the Bill & Melinda Gates Foundation Investment, classified as mezzanine equity. |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Allowance for doubtful accounts | $ 478 | $ 478 |
Related party accounts receivable allowace | $ 23 | $ 23 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 287,973,020 | 274,108,808 |
Common stock, shares outstanding (in shares) | 287,973,020 | 274,108,808 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Renewable product sales | $ 8,292,000 | $ 3,140,000 |
Grants and collaborations revenue | 4,688,000 | 5,671,000 |
Total revenues | 12,980,000 | 8,811,000 |
Cost and operating expenses | ||
Cost of products sold | 12,768,000 | 11,178,000 |
Research and development | 14,778,000 | 11,906,000 |
Sales, general and administrative | 12,778,000 | 12,266,000 |
Total cost and operating expenses | 40,324,000 | 35,350,000 |
Loss from operations | (27,344,000) | (26,539,000) |
Other income (expense): | ||
Interest income | 61,000 | 57,000 |
Interest expense | (12,184,000) | (8,359,000) |
Gain from change in fair value of derivative instruments | 2,339,000 | 21,678,000 |
Gain/(loss) upon extinguishment of debt | 96,000 | (216,000) |
Other expense, net | (380,000) | (1,814,000) |
Total other income (expense) | (10,068,000) | 11,346,000 |
Loss before income taxes | (37,412,000) | (15,193,000) |
(Benefit from)/provision for income taxes | 41,000 | (115,000) |
Net loss | (37,371,000) | (15,308,000) |
Net loss attributable to noncontrolling interest | ||
Net loss attributable to Amyris, Inc. common stockholders | $ (37,371,000) | $ (15,308,000) |
Net loss per share attributable to common stockholders: | ||
Basic (in dollars per share) | $ (0.13) | $ (0.07) |
Diluted (in dollars per share) | $ (0.13) | $ (0.12) |
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock: | ||
Basic (in shares) | 290,039,216 | 207,199,563 |
Diluted (in shares) | 290,039,216 | 260,932.09 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Comprehensive loss: | ||
Net loss | $ (37,371) | $ (15,308) |
Foreign currency translation adjustment, net of tax | 323 | 4,687 |
Total comprehensive loss | (37,048) | (10,621) |
Loss attributable to noncontrolling interest | 0 | 0 |
Comprehensive loss attributable to Amyris, Inc. | $ (37,048) | $ (10,621) |
Condensed Consolidated Stateme6
Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - 3 months ended Mar. 31, 2017 - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Noncontrolling Interest [Member] | Mezzanine Equity [Member] | Total |
Balance (in shares) at Dec. 31, 2016 | 274,108,808 | ||||||
Balance at Dec. 31, 2016 | $ 27 | $ 990,870 | $ (1,134,438) | $ (40,904) | $ 937 | $ 5,000 | $ (183,508) |
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares) | 500 | 500 | |||||
Issuance of common stock for settlement of debt principal payments (in shares) | 13,546,448 | ||||||
Interest capitalized to debt | $ 1 | 7,680 | $ 1,115 | ||||
Shares issued from restricted stock settlement (in shares) | 317,264 | ||||||
Shares issued from restricted stock settlement | (22) | (22) | |||||
Stock-based compensation | 1,646 | 1,646 | |||||
Foreign currency translation adjustment, net of tax | 323 | 323 | |||||
Net income (loss) | (37,371) | (37,371) | |||||
Balance (in shares) at Mar. 31, 2017 | 287,973,020 | ||||||
Balance at Mar. 31, 2017 | $ 28 | $ 1,000,174 | $ (1,171,809) | $ (40,581) | $ 937 | $ 5,000 | $ (211,251) |
Condensed Consolidated Stateme7
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Operating activities | ||
Net loss | $ (37,371,000) | $ (15,308,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 2,715,000 | 2,869,000 |
Loss on disposal of property, plant and equipment | (55,000) | (37,000) |
Stock-based compensation | 1,646,000 | 2,051,000 |
Amortization of debt discount and issuance costs | 4,473,000 | 2,994,000 |
(Gain)/loss upon extinguishment of debt | (96,000) | 216,000 |
Gain from change in fair value of derivative instruments | (2,339,000) | (21,678,000) |
(Gain)/loss on foreign currency exchange rates | (295,000) | 1,117,000 |
Changes in assets and liabilities: | ||
Accounts receivable | 4,888,000 | (1,484,000) |
Related party accounts receivable | 500,000 | (300,000) |
Inventories, net | (867,000) | 3,870,000 |
Prepaid expenses and other assets | (713,000) | 1,288,000 |
Accounts payable | 450,000 | (810,000) |
Accrued and other liabilities | 3,730,000 | 2,924,000 |
Deferred revenue | (1,844,000) | (1,292,000) |
Deferred rent | (215,000) | (163,000) |
Net cash used in operating activities | (25,393,000) | (23,743,000) |
Investing activities | ||
Purchase of short-term investments | (1,781,000) | (1,377,000) |
Maturities of short-term investments | 2,094,000 | 1,627,000 |
Change in restricted cash | 4,040,000 | 13,000 |
Purchases of property, plant and equipment, net of disposals | (457,000) | (271,000) |
Net cash provided by (used in) investing activities | 3,896,000 | (8,000) |
Financing activities | ||
Employees' taxes paid upon vesting of restricted stock units | (22,000) | (48,000) |
Principal payments on capital leases | (627,000) | (160,000) |
Proceeds from debt issued | 1,500,000 | |
Proceeds from debt issued to related party | 20,000,000 | |
Principal payments on debt | (4,273,000) | (729,000) |
Net cash provided by (used in) financing activities | (3,762,000) | 19,063,000 |
Effect of exchange rate changes on cash and cash equivalents | (83,000) | 522,000 |
Net decrease in cash and cash equivalents | (25,853,000) | (4,166,000) |
Cash and cash equivalents at beginning of period | 27,150,000 | 11,992,000 |
Cash and cash equivalents at end of period | 1,297,000 | 7,826,000 |
Supplemental disclosures of cash flow information: | ||
Cash paid for interest | 1,863,000 | 990,000 |
Acquisitions of property, plant and equipment under accounts payable, accrued liabilities and notes payable | (821,000) | (521,000) |
Financing of equipment | 180,000 | 100,000 |
Financing of insurance premium under notes payable | (146,000) | (159,000) |
Issuance of common stock for settlement of debt principal and interest payments | 7,681,000 | |
Interest capitalized to debt | 1,115,000 | 1,010,000 |
Purchase of property, plant and equipment via deposit | 24,000 | |
Non-cash investment in joint venture | 600,000 | |
Cancellation of debt and accrued interest on disposal of interest in affiliate | $ 4,252,000 |
Note 1 - The Company
Note 1 - The Company | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Amyris, Inc. (or the Company) was incorporated in California on July 17, 2003 April 15, 2010 first 2014, 2015 2016 one The Company's renewable products business strategy is to generally focus on direct commercialization of specialty products while moving established commodity products into joint venture arrangements with leading industry partners. To commercialize its products, the Company must be successful in using its technology to manufacture its products at commercial scale and on an economically viable basis (i.e., low per unit production costs) and developing sufficient sales volume for those products to support its operations. The Company's prospects are subject to risks, expenses and uncertainties frequently encountered by companies in this stage of development. Liquidity The Company expects to fund its operations for the foreseeable future with cash and investments currently on hand, with cash inflows from collaborations and grants, with cash contributions from product sales, with new debt and equity financings and with proceeds from strategic asset divestments. The Company's planned 2017 2018 The Company has incurred significant operating losses since its inception and believes that it will continue to incur losses and negative cash flow from operations into at least 2018. March 31, 2017, $77.6 $1,171.8 $2.5 second 2017 18, March 31, 2017. one may may As of March 31, 2017, $42.0 $220.9 $49.5 twelve $20.8 5, 6, 18, In addition to the need for financing described above, the Company may second 2017 2017 2018: • Effect significant headcount reductions, particularly with respect to employees not connected to critical or contracted activities across all functions of the Company, including employees involved in general and administrative, research and development, and production activities. • Shift focus to existing products and customers with significantly reduced investment in new product and commercial development efforts. • Reduce production activity at the Company’s Brotas manufacturing facility to levels only sufficient to satisfy volumes required for product revenues forecast from existing products and customers. • Reduce expenditures for third • Reduce or delay uncommitted capital expenditures, including non-essential facility and lab equipment, and information technology projects. • Closely monitor the Company’s working capital position with customers and suppliers, as well as suspend operations at pilot plants and demonstration facilities. Implementing this plan could have a negative impact on the Company's ability to continue its business as currently contemplated, including, without limitation, delays or failures in its ability to: • Achieve planned production levels; • Develop and commercialize products within planned timelines or at planned scales; and • Continue other core activities. Furthermore, any inability to scale-back operations as necessary, and any unexpected liquidity needs, could create pressure to implement more severe measures. Such measures could have an adverse effect on the Company's ability to meet contractual requirements, including obligations to maintain manufacturing operations, and increase the severity of the consequences described above. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (or “GAAP”) and with the instructions for Form 10 10 December 31, 2016 April 17, 2017. The Company uses the equity method to account for investments in companies, if its investments provide it with the ability to exercise significant influence over operating and financial policies of the investee. Consolidated net income or loss includes the Company’s proportionate share of the net income or loss of these companies. Judgments made by the Company regarding the level of influence over each equity method investment include considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. Principles of Consolidation The condensed consolidated financial statements of the Company include the accounts of Amyris, Inc., its subsidiaries and two 7, Variable Interest Entities The Company has interests in joint venture entities that are VIEs. Determining whether to consolidate a VIE requires judgment in assessing (i) whether an entity is a VIE and (ii) if the Company is the entity’s primary beneficiary and thus required to consolidate the entity. To determine if the Company is the primary beneficiary of a VIE, the Company evaluates whether it has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company’s evaluation includes identification of significant activities and an assessment of its ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding and financing and other applicable agreements and circumstances. The Company’s assessment of whether it is the primary beneficiary of its VIEs requires significant assumptions and judgment. Use of Estimates In preparing the unaudited condensed consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, except for the impact of adoption of certain accounting standards as described below, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the quarter ended March 31, 2017 2015 11, Simplifying the Measurement of Inventory 2016 06, Contingent Put and Call Options in Debt Instruments 2016 09, Compensation - Stock Compensation (Topic 718): The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. Recent Accounting Pronouncements In November 2016, 2016 18 Statement of Cash Flows - Restricted Cash. December 15, 2017, In October 2016, 2016 16, Intra-Entity Transfers of Assets Other Than Inventory December 15, 2017. first 2017. In August 2016, 2016 15 Classification of Certain Cash Receipts and Cash Payments December 15, 2017 In June 2016, 2016 13, Allowance for Loan and Lease Losses (Financial Instruments - Credit Losses Topic 326) December 15, 2019, December 15, 2018, In February 2016, Update2016 02 Leases December 15, 2018. may In January 2016, 2016 01 Financial Instruments-Overall December 15, 2017, In May 2014, March, April, May December 2016, 2016 08); 2016 10) 2016 12). July 9, 2015, one December 15, 2017 December 15, 2016. March 31, 2018. may |
Note 3 - Fair Value of Financia
Note 3 - Fair Value of Financial Instruments | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Financial Instruments Disclosure [Text Block] | 3. The inputs to the valuation techniques used to measure fair value are classified into the following categories: Level 1: Level 2: Level 3: There were no transfers between the levels, and as of March 31, 2017, Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 297 $ — $ — $ 297 Certificates of deposit 1,188 — — 1,188 Total financial assets $ 1,485 $ — $ — $ 1,485 Financial Liabilities Loans payable (1) $ — $ 51,378 $ — $ 51,378 Credit facilities (1) — 50,891 — 50,891 Convertible notes (1) — — 115,268 115,268 Compound embedded derivative liabilities — — 2,728 2,728 Currency interest rate swap derivative liability — 2,961 — 2,961 Total financial liabilities $ — $ 105,230 $ 117,996 $ 223,226 ________ (1) The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The fair values of money market funds and certificates of deposit are based on fair values of identical assets. The fair values of the loans payable, convertible notes, credit facilities and currency interest rate swaps are based on the present value of expected future cash flows and assumptions about current interest rates and the creditworthiness of the Company. The method of determining the fair value of the compound embedded derivative liabilities is described subsequently in this note. Market risk associated with the fixed and variable rate long-term loans payable, credit facilities and convertible notes relates to the potential reduction in fair value and negative impact to future earnings, from an increase in interest rates. Market risk associated with the compound embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. As of December 31, 2016, Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,373 — — 1,373 Total financial assets $ 2,922 $ — $ — $ 2,922 Financial Liabilities Loans payable (1) $ — $ 53,579 $ — $ 53,579 Credit facilities (1) — 51,261 — 51,261 Convertible notes (1) — — 117,767 117,767 Compound embedded derivative liabilities — — 4,135 4,135 Currency interest rate swap derivative liability — 3,343 — 3,343 Total financial liabilities $ — $ 108,183 $ 121,902 $ 230,085 _______ (1) July 29, 2015, 5 18, The following table provides a reconciliation of the beginning and ending balances for the convertible notes disclosed at fair value using significant unobservable inputs (Level 3) 2017 Balance at January 1 $ 117,767 New instruments 15,049 Conversion/extinguishment of convertible notes (21,077 ) Change in fair value of convertible notes 3,529 Balance at March 31 $ 115,268 Derivative Instruments The following table provides a reconciliation of the beginning and ending balances for the compound embedded derivative liabilities measured at fair value using significant unobservable inputs (Level 3) 2017 Balance at January 1 $ 4,135 Gain from change in fair value of derivative liabilities (1,984 ) Additions 577 Balance at March 31 $ 2,728 The compound embedded derivative liabilities represent the fair value of the equity conversion options and "make-whole" provisions, as well as the down round conversion price adjustment or conversion rate adjustment provisions of the R&D Notes, the Tranche I Notes, the Tranche II Notes, the 2014 144A 2015 144A 5, 2014 144A 2015 144A may two one (1) (2) March 31, 2017 December 31, 2016, $2.7 $4.1 The market-based assumptions and estimates used in valuing the compound embedded derivative liabilities include amounts in the following ranges/amounts: March 31, 2017 March 31, 2016 Risk-free interest rate 0.74% - 1.30% 0.80% - 0.89% Risk-adjusted yields 12.50% - 22.63% 35.00% - 45.13% Stock-price volatility 45% 45% Probability of change in control 5% 5% Stock price $0.53 $1.11 Credit spread 11.28% - 21.35% 34.16% - 44.25% Estimated conversion dates 2017 - 2019 2016 - 2019 Changes in valuation assumptions can have a significant impact on the valuation of the embedded derivative liabilities. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. The conversion price of certain of the Convertible Notes also include conversion price adjustment features and for, example, issuances of common stock by the Company at prices lower than the conversion price result in a reset of the conversion price of such notes, which increases the value of the embedded derivative liabilities. See Note 5, In June 2012, 5, R$22.0 US$6.9 March 31, 2017) 3.94%. Type of Derivative Income Three Months Ended March 31, 2017 2016 Currency interest rate swap Gain from change in fair value of derivative instruments $ 355 $ 845 Derivative instruments measured at fair value as of March 31, 2017 December 31, 2016, March 31, December 31, Fair market value of compound embedded derivative liabilities $ 2,150 $ 4,135 Non-current fair value of swap obligations 2,979 3,343 Total derivative liabilities $ 5,129 $ 7,478 |
Note 4 - Balance Sheet Componen
Note 4 - Balance Sheet Components | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 4. Inventories, net Inventories, net are stated at the lower of cost or net realizable value and comprise of the following (in thousands): March 31, December 31, Raw materials $ 3,038 $ 3,159 Work-in-process 1,343 1,848 Finished goods 2,696 1,206 Inventories, net $ 7,077 $ 6,213 Property, Plant and Equipment, net Property, plant and equipment, net is comprised of the following (in thousands): March 31, December 31, Machinery and equipment $ 84,853 $ 82,688 Leasehold improvements 38,828 38,785 Computers and software 9,658 9,585 Buildings 4,834 4,699 Furniture and office equipment 2,350 2,333 Vehicles 136 164 Land 460 460 Construction in progress 2,465 2,216 143,584 140,930 Less: accumulated depreciation and amortization (90,539 ) (87,195 ) Property, plant and equipment, net $ 53,045 $ 53,735 The Company's first, December 2012. Property, plant and equipment, net includes $3.1 $3.1 March 31, 2017 December 31, 2016, $0.1 $0.6 March 31, 2017 December 31, 2016, Depreciation and amortization expense, including amortization of assets under capital leases was $2.7 $2.9 three March 31, 2017 2016, Other Assets (non-current) Other assets are comprised of the following (in thousands): March 31, December 31, Recoverable taxes from Brazilian government entities $ 14,894 $ 13,723 Deposits on property and equipment, including taxes 499 291 Other 1,401 1,450 Total other assets $ 16,794 $ 15,464 Accrued and Other Current Liabilities Accrued and other current liabilities are comprised of the following (in thousands): March 31, December 31, Withholding tax related to conversion of related party notes $ 1,370 $ 1,370 Professional services 5,358 6,876 SMA relocation accrual 3,746 3,641 Accrued interest 8,259 4,847 Tax-related liabilities 2,480 2,610 Accrued vacation 2,228 2,034 Payroll and related expenses 2,761 4,310 Deferred rent, current portion 1,111 1,111 Contractual obligations to contract manufacturers 381 — Other 1,960 2,389 Total accrued and other current liabilities $ 29,654 $ 29,188 |
Note 5 - Debt and Mezzanine Equ
Note 5 - Debt and Mezzanine Equity | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 5. Debt is comprised of the following (in thousands): March 31, 2017 December 31, 2016 Senior secured loan facility $ 27,844 $ 27,658 BNDES credit facility 904 1,172 FINEP credit facility 637 696 Guanfu credit facility 19,858 19,564 Total credit facilities 49,243 49,090 Convertible notes 75,218 78,981 Related party convertible notes 43,335 42,754 Related party loan payable 30,554 29,691 Loans payable 22,588 26,527 Total debt 220,938 227,043 Less: current portion (49,455 ) (59,155 ) Long-term debt $ 171,483 $ 167,888 Mezzanine equity $ 5,000 $ 5,000 Senior Secured Loan Facility In March 2014, $25.0 $25.0 6.25% 9.50%. may (October 15, 2018) 1% 1% 10% $25.0 In June 2014, first first May 31, 2015 February 1, 2017 $10.0 October 1, 2014, July 1, 2014, 3 June 30, 2014 $50.0 September 30, 2014. 50% $5.0 $5.0 June 2014, 5.25% 8.5%. In March 2015, second second $15.0 March 31, 2016 $20.0 second 3.0% April 1, 2015. June 30, 2015 $20.0 June 30, 2015, 5.0% June 30, 2015. June 30, 2015, 5.0% June 30, 2015. July 2015. In November 2015, third third $10,960,000 November 30, 2015. December 1, 2015, $9.1 third $31.7 9.5% 6.25%,. $767,200. third $1.0 $750,000 $15.0 second $250,000 third December 1, 2015, February 29, 2016. March 1, 2016, third 2016, December 1, 2016. $20.0 February 2016 $20.0 May 31, 2016. June 1, 2016, June 2016, June 29, 2016, October 31, 2016. 8, October 6, 2016, fourth $1 January 11, 2017, October 15, 2018 December 2016, 7, $425,000 December 31, 2017 $450,000 January 2017, fifth fifth $3 As of March 31, 2017, $27.8 $0.7 may BNDES Credit Facility In December 2011, R$22.4 US$7.1 March 31, 2017). R$19.1 R$3.3 2013. The principal of the loans under the BNDES Credit Facility is required to be repaid in 60 first January 2013 December 2017. first March 2012. January 2013, 7% 0.1% The BNDES Credit Facility is collateralized by a first R$24.9 $7.9 March 31, 2017). 10% (R$22.4 second R$19.1 90% 130% may March 31, 2017 December 31, 2016, R$2.9 US$0.9 March 31, 2017) R$3.8 US$1.2 December 31, 2016), FINEP Credit Facility In November 2010, R$6.4 US$2.0 March 31, 2017), Interest on loans drawn under the FINEP Credit Facility is fixed at 5% 6%, 5% 11% 10% 1% 81 July 2012 March 2019. March 2011. March 31, 2017 December 31, 2016, R$2.0 US$0.7 March 31, 2017) R$2.3 US$0.7 December 31, 2016), Guanfu Credit Facility On October 26, 2016, $25.0 three November 16, 2016, December 1, 2016, December 31, 2016. December 31, 2016, $25.0 five 10% March 31, 2017. may, 100% Upon the occurrence of certain specified events of default under the Guanfu Credit Facility, the Company will grant to Guanfu an exclusive, royalty-free, global license to certain intellectual property useful in connection with Guanfu’s existing commercial relationship with the Company. In addition, in the event the Company fails to pay interest or principal under the Guanfu Note within ten 90% 90 two Convertible Notes Fidelity In February 2012, $25.0 3% March 1, 2017 $7.0682 October 2015, $57.6 $8.8 $9.7 March 31, 2017, 2,165,898 101% $200.0 50% $125.0 30% $35.0 October 2013 August 2013 $7.6 first August 2013 5, December 28, 2016, $19.1 2015 144A 1:1.25 i.e $1.00 $1.25 2015 144A 1933, January 11, 2017. $19.1 2015 144A 2015 144A 2015 144A $0.1 first 2015 144A fourth October 15, 2018. fourth 2014 144A In May 2014, $75.0 6.50% 2019 2014 144A 2014 144A $15.0 2014 144A 2014 144A May 29, 2014 2014 2014 144A $72.0 2014 144A $9.7 2014 144A $24.7 2014 144A October 2015, $57.6 $18.3 $22.9 2014 144A 2014 144A 6.50% May 15 November 15 November 15, 2014. 2014 144A May 15, 2019, 2014 144A 2014 144A 267.037 $1,000 2014 144A $3.74 May 15, 2015, 20 30 five 2014 144A three (May 15, 2019), 0.75%. 2014 2014 144A may 2014 144A 100% 2014 144A 2014 144A 2014 144A 5, 18, 2014 144A 2015 144A In October 2015, $57.6 9.50% 2019 2015 144A 2015 144A 2015 144A October 20, 2015 2015 2015 144A $54.4 $18.3 $22.9 2014 144A $8.8 $9.7 2015 144A 2015 144A 9.50% April 15 October 15 April 15, 2016. 2015 144A April 15, 2016 October 15, 2016 April 15, 2017 2015 144A April 15, 2019 The 2015 144A April 15, 2019. 2015 144A 443.6557 $1,000 2015 144A $2.25 February 2016 May, September October 2016, 2015 144A 446.8707 $1,000 2015 144A December 31, 2016. May 2017, 2015 144A 711.1209 $1,000 2015 144A May 11, 2017, $1.41 November 27, 2015, 2015 144A three (April 15, 2019), 0.75%. may may 92.5% 10 March 31, 2017, 2015 2015 144A may 2015 144A 100% 2015 144A 2015 144A 2015 144A 2015 144A 2015 144A 38,415,626 May 17, 2016. 2015 144A 2015 144A $25.0 $200.0 $65.0 30% January 2017, $19.1 2015 144A 2015 144A $15.3 2015 144A 2015 January 11, 2017, 2015 2015 144A 2015 144A 2015 144A 2015 144A 2015 144A 19.99% December 28, 2016 May 2016 In May 2016, May 2016 $15.0 May 2016 $1.90 May 2016 May 2016 first third May 2016 May 2016 Pursuant to the May 2016 May 2016 two May 10, 2016. May 2016 $10.0 $9.9 second first first three May 2016 second May 2016 $5.0 $5.0 September 2, 2016, second May 2016 May 2016 $3.0 $3.0 May 2016 $2.0 May 2016 May 2016 May 2016 December 31, 2016. October 13, 2016, May 2016 $2.0 The May 2016 May 2016 18 The May 2016 118% May 2016 May 2016 50% $200,000. May, June, July, August, September October 2016 May 2016 October 31, 2016, May 2016 The May 2016 may May 2016 118% In the event of a Fundamental Transaction (as defined in the May 2016 May 2016 may May 2016 118% The Company has the right to redeem the May 2016 118% May 2016 $1.00 30 $0.50 five four 2016 May 2016 112% May 2016 Notwithstanding the foregoing, the holders will not have the right to convert any portion of a May 2016 may May 2016 4.99% 9.99%, 61 May 2016 19.99% May 10, 2016. May 2016 For as long as they hold the May 2016 May 2016 may $1.05 May 2016 $1.00, may The May 2016 March 31, 2017. December 2016 On December 1, 2016, December 2016 $10.0 December 2016 $1.90 December 2016 first third December 2016 December 2016 The December 2016 December 2, 2016, $9.9 The December 2016 December 2016 May 1, 2018, The December 2016 January 1, 2017, 118% December 1, 2016 December 31, 2016, December 2016 December 2016 50% $200,000. The December 2016 may December 2016 118% In the event of a Fundamental Transaction (as defined in the December 2016 December 2016 may December 2016 118% The Company has the right to redeem the December 2016 118% December 2016 Notwithstanding the foregoing, the holder will not have the right to convert any portion of the December 2016 4.99% 9.99%, 61 December 2016 19.99% December 1, 2016. December 2016 For as long as it holds the December 2016 December 2016 may $1.05 December 2016 $1.00, may March 31, 2017 December 31, 2016. In May 2017, December 2016 18, See Note 18, March 31, 2017. Related Party Convertible Notes Total R&D Convertible Notes In July 2012 December 2013, The purchase agreement for the notes related to the funding from Total (or the Total Purchase Agreement) provided for the sale of an aggregate of $105.0 1.5% March 2017 • As part of an initial closing under the purchase agreement (which was completed in two July 30, 2012, $38.3 $15.0 $23.3 September 14, 2012, $15.0 $7.0682 • At a second two $30.0 ($10.0 June 2013 $20.0 July 2013). $3.08 • At a third two $21.7 ($10.85 July 2014 $10.85 January 2015). $4.11 In March 2013, March 2013 July 2013 July 2013 $30.0 • Reduce the conversion price for the $30.0 second $7.0682 March 2013 $0.01, $3.08 • Grant Total a senior security interest in the Company's intellectual property, subject to certain exclusions and subject to release by Total when the Company and Total enter into final documentation regarding the establishment of the Fuels JV. In addition to the waiver by Total described above, Total also agreed that, at the Company's request and contingent upon the Company meeting its obligations described above, it would pay advance installments of the amounts otherwise payable at the second In June 2013, $10.0 second March 2013 $3.08 In July 2013, $20.0 second $30.0 second July 2013. March 2013 $3.08 In December 2013, December 2, 2013 December 2, 2013 7, $69.0 1.5% March 2017 third October 16, 2013, December 2, 2013 In April 2014, March 29, 2014 March 2014 December 2, 2013 March 2014 third $7.0682 $4.11 2014 May 2014), may June 30, 2014 December 31, 2014 $75.0 third March 31, 2014, third In July 2014, $10.85 March 1, 2017 $21.7 third March 2014 $4.11 In January 2015, $10.85 March 1, 2017 $21.7 third March 2014 $4.11 In July 2015, $5.0 $70 30.4 5, In March 2016, 7, one 75% 25% $1.3 ($2.8 July 29, 2015) 50,000, $5.0 $3.7 25% $4.2 As of March 31, 2017 December 31, 2016, $3.7 $3.7 February 2017, March 1, 2017 May 15, 2017. 1.5% 2.5%), The R&D Notes become convertible into the Company's common stock (i) within 10 101% may $200.0 50% may $125.0 30% August 2013 In August 2013, August 2013 $73.0 August 2013 24 August 2013 August 2013 two first $42.6 second $30.4 $25.0 ($25.0 second $35.0 $13.0 ($7.6 first $5.4 second August 2013 second 1,000,000 $0.01 second September 2013, August 2013 $110.0 1,000,000 August 2013 In October 2013, $35.0 February 2, 2014 5.5% October 4, 2013 October 16, 2013 first August 2013 In October 2013, August 2013 first August 2013 $7.6 first $9.2 first October 2013, first August 2013 $51.8 $7.6 $44.2 $35.0 $9.2 $35.0 $9.2 $19.9 sixty $2.44 15% 60 August 7, 2013, 18 August 2013 5% six 6.5% first 180 8% 6.5% first 30 six may six may March 31, 2017, may 30 six In December 2013, August 2013 $3.0 second August 2013 $25.0 January 2014, $34.0 second August 2013 $25.0 $3.0 $6.0 $6.0 $9.4 sixty $2.87 60 August 7, 2013, 12 10%, 13% first 180 16% 12% first 36 may may The conversion prices of the Tranche I Notes and Tranche II Notes are subject to adjustment (i) according to proportional adjustments to outstanding common stock of the Company in case of certain dividends and distributions, (ii) according to anti-dilution provisions, and (iii) with respect to notes held by any purchaser other than Total, in the event that Total exchanges existing convertible notes for new securities of the Company in connection with future financing transactions in excess of its pro rata amount. The holders have a right to require repayment of 101% August 2013 August 2013 may In July 2015, $71.0 30.86 5, The conversion price of the Tranche I Notes and Tranche II Notes was reduced to approximately $1.42 July 2015, February 2016, $1.40 May 2016, $1.14 May 2017, 18, $0.50 As of March 31, 2017 December 31, 2016, $22.1 $21.8 $0.0 $0.0 5, 2014 144A As of March 31, 2017 December 31, 2016, 2014 144A $17.6 $17.3 $7.1 $7.4 As of March 31, 2017 December 31, 2016, $43.3 $42.8 $5.6 $5.4 Loans Payable In July 2012, "July 2012 July 2012 R$52.0 R$68.0 US$21.5 March 31, 2017). July 2012 R$52.0 US$16.4 March 31, 2017) R$22.0 R$30.0 July 15, 2022 5.5% 30 first two August 15, 2014, March 31, 2017 December 31, 2016, $10.9 $11.1 Exchange (Debt Conversion - Related Party Transaction) On July 29, 2015, July 26, 2015 Under the Exchange Agreement, at the closing of the Exchange, Temasek exchanged $71.0 July 29, 2015) $70.0 $2.30 30,860,633 30,434,782 $39.2 December 31, 2015. Under the Exchange Agreement, Total also received the following warrants, each with a five • A warrant to purchase 18,924,191 • A warrant to purchase 2,000,000 March 1, 2017, Additionally, under the Exchange Agreement, Temasek received the following warrants: • A warrant to purchase 14,677,861 • A warrant exercisable for that number of shares of the Company’s common stock equal to (1) may 2,000,000, 30.6% 69.4% (2) may 13.3% 86.7% • A warrant exercisable for that number of shares of the Company’s common stock equal to 880,339 2,000,000 880,339 The Temasek Exchange Warrant, the Temasek Funding Warrant and the Temasek R&D Warrant each have ten $0.01 In addition to the grant of the Exchange Warrants, a warrant issued by the Company to Temasek in October 2013 2013 1,000,000 2013 $0.01 The exercisability of all of the Exchange Warrants was subject to stockholder approval, which was obtained on September 17, 2015. In February May 2016, 127,194 2,335,342 May 2017, 18, 16,886,320 As of March 1, 2017, March 1, 2017 880,339 2,000,000. As of March 31, 2017, 2013 12,700,244 March 31, 2017. 2,462,536 March 31, 2017 Maturity Treatment Agreement At the closing of the Exchange, the Company, Total and Temasek also entered into a Maturity Treatment Agreement, dated as of July 29, 2015, 2014 144A $10.0 2014 144A $25.0 $9.7 2014 144A $15.3 18, February 2016 On February 12, 2016, February 2016 $18.0 February 2016 2,571,428 $0.01 $18 February 15, 2016, February 2016 $2.0 February 2016 285,714 $0.01 $2 February 2016 February 2016 $16.0 February 2016 2,285,714 $2.0 February 2016 285,714 $2.0 February 2016 285,714 February 12, 2016, February 15, 2016. The February 2016 February 12, 2016, February 2016 February 12, 2016, February 15, 2016, 13.50% May 15, 2017, February 2016 February 2016 February 2016 February 2016 February 2016 may February 2016 The exercisability of the warrants issued in the February 2016 five May 17, 2016. March 31, 2017, February 2016 $19.6 In May 2017, 18, $18.0 February 2016 June 2016 On June 24, 2016, June 2016 $5.0 June 2016 $5.0 June 2016 June 2016 June 2016 June 24, 2016. The June 2016 second June 24, 2016, June 2016 June 24, 2016 13.50% May 15, 2017, June 2016 June 2016 June 2016 June 2016 June 2016 may June 2016 In May 2017, 18, June 2016 October 2016 On October 21 October 27, 2016, October 2016 $6.0 $8.5 October 2016 $6.0 $8.5 October 2016 October 2016 October 2016 October 21 October 27, 2016, The October 2016 second October 2016 October 2016 October 21 27, 2016, 13.50% May 15, 2017, October 2016 October 2016 October 2016 October 2016 October 2016 may October 2016 In May 2017, 18, October 2016 October 2016 Salisbury Note In December 2016, 7, $3.5 5% 13 January 1, 2017 5% 5 may may January 2017, Nikko Note In December 2016, 7, $3.9 5% 13 January 1, 2017 5% 5 first 10% $400,000 $100,000 January 1, 2017, February 1, 2017, March 1, 2017 April 1, 2017 fourth may may In February 2017, $1.5 $375,000 May 1, 2017, August, 2017, November 1, 2018 February 1, 2018. 2.75% Letters of Credit In June 2012, $1.0 $1.0 March 31, 2017 December 31, 2016. Future minimum payments under the debt agreements as of March 31, 2017 Years ending December 31: Related Party Convertible Loans Related Credit Total 2017 (remaining nine months) $ 4,537 $ 12,677 $ 11,899 $ 31,511 $ 5,271 $ 65,895 2018 16,290 21,803 2,878 — 33,710 74,681 2019 34,913 93,287 2,766 — 2,580 133,546 2020 — — 2,656 — 2,500 5,156 2021 — — 2,543 — 27,396 29,939 Thereafter — — 1,442 — — 1,442 Total future minimum payments (1) 55,740 127,767 24,184 31,511 71,457 310,659 Less: amount representing interest (2) (12,405 ) (52,549 ) (1,596 ) (957 ) (22,214 ) (89,721 ) Present value of minimum debt payments 43,335 75,218 22,588 30,554 49,243 220,938 Less: current portion (3,611 ) (2,288 ) (11,780 ) (30,554 ) (1,222 ) (49,455 ) Noncurrent portion of debt $ 39,724 $ 72,930 $ 10,808 $ — $ 48,021 $ 171,483 ______________ (1) $3.9 2017 may $46.8 2018 2019 18, (2) $42.0 |
Note 6 - Commitments and Contin
Note 6 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Commitments Contingencies and Guarantees [Text Block] | 6. Lease Obligations The Company leases certain facilities and finances certain equipment under operating and capital leases, respectively. Operating leases include leased facilities and capital leases include leased equipment (see Note 4, tenant February 2031. $1.3 three March 31, 2017 2016, Future minimum payments under the Company's lease obligations as of March 31, 2017, Years ending December 31: Capital Operating Total Lease 2017 (remaining nine months) $ 734 $ 5,194 $ 5,928 2018 106 6,909 7,015 2019 9 6,782 6,791 2020 — 7,012 7,012 2021 — 7,248 7,248 Thereafter — 10,993 10,993 Total future minimum lease payments 849 $ 44,138 $ 44,987 Less: amount representing interest (39 ) Present value of minimum lease payments 810 Less: current portion (405 ) Long-term portion $ 405 Guarantor Arrangements The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of March 31, 2017 December 31, 2016. The Company entered into the FINEP Credit Facility to finance a research and development project on sugarcane-based biodiesel (see Note 5, R$6.0 US$1.9 March 31, 2017). The Company entered into the BNDES Credit Facility to finance a production site in Brazil (see Note 5, first R$24.9 US$7.9 March 31, 2017). The Company entered into loan agreements and security agreements whereby the Company pledged certain farnesene production assets as collateral (the fiduciary conveyance of movable goods) with each of Nossa Caixa and Banco Pine (see Note 5, R$68.0 US$21.5 March 31, 2017). In December 2013, 5, 7, $69.0 1.5% March 2017, $10.85 third July 2014 $10.85 second third January 2015 5,"Debt March 2016, 5, 7, $3.7 February 2017, March 1, 2017 May 15, 2017. The Senior Secured Loan Facility and the June 2016 October 2016 5, first second first 10% Purchase Obligations As of March 31, 2017 December 31, 2016, $3.7 $0.8 zero $0.6 Production Cost Commitment As of March 31, 2017, March 31, 2017 three $10 Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed. The Company has levied indirect taxes on sugarcane-based biodiesel sales by Amyris Brasil to customers in Brazil based on advice from external legal counsel. In the absence of definitive rulings from the Brazilian tax authorities on the appropriate indirect tax rate to be applied to such product sales, the actual indirect rate to be applied to such sales could differ from the rate we levied. In April 2017, March 2, 2017 April 17, 2017. March 2, 2017 12b 25 April 3, 2017. The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may one |
Note 7 - Joint Ventures and Non
Note 7 - Joint Ventures and Noncontrolling Interest | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | 7. Novvi LLC In September 2011, March 2013, first may December 31, 2015 50% six 20 50% $10.0 50% $10.0 March 2013, zero. In April 2014, $0.2 April 2014, $2.1 50% In September 2014, $3.7 September 1, 2017 0.36% September 1, 2017. 50% $1.8 two first $1.2 September 2014 second $0.6 October 2014. November 2014, second $1.9 September 2014, November 10, 2017. 50% $1.0 November 2014. May 2015, third $1.1 September 2014, May 14, 2018. 50% In the fourth 2015, four $1.6 September 2014, August 19, 2018, October 15, 2018, November 12, 2018 December 17, 2018. 50% four July 2016, seven In February 2016, $0.6 $0.6 50% On July 19, 2016, $10.0 one third seven three one third two July 19, 2016. July 19, 2016. March 31, 2017, $10.0 In November 2016, $1.0 20,000 3% 25% may, Additional funding requirements to finance the ongoing operations of Novvi are expected to happen through revolving credit or other loan facilities provided by unrelated parties (i.e., such as financial institutions); cash advances or other credit or loan facilities provided by Novvi’s members or their affiliates; or additional capital contributions by the existing Novvi members or new investors. The Company has identified Novvi as a VIE and determined that the power to direct activities which most significantly impact the economic success of the joint venture (i.e., continuing research and development, marketing, sales, distribution and manufacturing of Novvi products) are shared among the Company, Cosan U.S. and ARG. Accordingly, the Company is not the primary beneficiary and therefore accounts for its investment in Novvi under the equity method of accounting. The Company will continue to reassess its primary beneficiary analysis of Novvi if there are changes in events and circumstances impacting the power to direct activities that most significantly affect Novvi's economic success. Under the equity method, the Company's share of profits and losses and impairment charges on investments in affiliates (nil for both periods presented) are included in “Loss from investments in affiliates” in the condensed consolidated statements of operations. The carrying amount of the Company's equity investment in Novvi was zero March 31, 2017 2016. Total Amyris BioSolutions B.V. In November 2013, March 2016 December 2, 2013 5, 8, In July 2015, February 2016, On February 12, 2016, $1.3 July 29, 2015), 50,000, 25% 75% 25% $3.7 On March 21, 2016, 5, Under the Jet Fuel Agreement, (a) the Company granted exclusive (co-exclusive in Brazil), world-wide, royalty-free rights to TAB for the production and commercialization of farnesene- or farnesane-based jet fuel, (b) the Company granted TAB the option, until March 1, 2018, Upon all farnesene-or farnesane-based diesel fuel rights reverting back to the Company, the Company granted to Total, pursuant to the EU Diesel Fuel Agreement, (a) an exclusive, royalty-free license to offer for sale and sell farnesene- or farnesane-based diesel fuel in the EU, (b) the non-exclusive right to make farnesene or farnesane anywhere in the world, but Total must (i) use such farnesene or farnesane to produce only diesel fuel to offer for sale or sell in the EU and (ii) pay the Company a to-be-negotiated, commercially reasonable, “most-favored” basis royalty and (c) the right to purchase farnesene or farnesane for its EU diesel fuel business from the Company on a “most-favored” pricing basis. As a result of the EU Diesel Fuel Agreement, the Company generally no longer has an independent right to make or sell, without the approval of Total, farnesene- or farnesane-based diesel fuels in the EU. As a result of, and in order to reflect, the changes to the ownership structure of TAB described above, on March 21, 2016, December 2, 2013 April 1, 2015, As of March 31, 2017, 25% 75% March 31, 2017 €0.1 US$0.1 March 31, 2017). SMA Indústria Química S.A. In April 2010, 20 SMA was initially managed by a three two one four two The joint venture agreements required the Company to fund the construction costs of the new facility and SMSA would reimburse the Company up to R$61.8 US$19.5 March 31, 2017) first four four Under the terms of the joint venture agreements, if the Company became controlled, directly or indirectly, by a competitor of SMSA, then SMSA would have the right to acquire the Company’s interest in SMA. If SMSA became controlled, directly or indirectly, by a competitor of the Company, then the Company would have the right to sell its interest in SMA to SMSA. In either case, the purchase price would be determined in accordance with the joint venture agreements, and the Company would continue to have the obligation to acquire products produced by SMA for the remainder of the term of the supply agreement then in effect even though the Company would no longer be involved in SMA’s management. The Company initially had a 50% March 31, 2017, 100% The Company completed a significant portion of the construction of the new facility in 2012. 2013 February 2014, 18 March 31, 2017, second December 31, 2018 second April 1, 2019. July 1, 2015 July 2015, December 2015, R$50,000 US$15,780 March 31, 2017), 50,000 January 11, 2016. 12 12 R$9,853 US$3,110 March 31, 2017). September 1, 2016, December 31, 2017. Salisbury transaction In January 2011, two February 1, 2011 one first On November 10, 2016, December 5, 2016, $4.35 $3.5 5, first Aprinnova JV On December 12, 2016, third March 2017, At the closing of the formation of the Neossance JV, which occurred on December 19, 2016, 50% $10 three $10 Pursuant to the Joint Venture Agreement, the Company and Nikko agreed to make working capital loans to the Aprinnova JV in the amounts of $500,000 $1,500,000, Under the Aprinnova JV Agreement, in the event of a merger, acquisition, sale or other similar reorganization, or a bankruptcy, dissolution, insolvency or other similar event, of the Company, on the one first In connection with the formation of the Aprinnova JV, the members entered into a First Amended and Restated LLC Operating Agreement of the Aprinnova JV (Operating Agreement). Pursuant to the Operating Agreement, the Aprinnova JV will be managed by a Board of Directors, which shall initially consist of four two two one one Under the Operating Agreement, profits from the operations of the Aprinnova JV, if any, will be distributed as follows: (i) first, zero second, (50%/50%) one In connection with the contribution of the Glycotech Assets by the Company to the Aprinnova JV, at the closing of the formation of the Aprinnova JV, Nikko made a loan to the Company in the principal amount of $3.9 5, The table below reflects the carrying amount of the assets and liabilities of the consolidated VIE for which the Company is the primary beneficiary at March 31, 2017. (In thousands) March 31, December 31, Assets $ 2,306 $ 2,277 Liabilities $ 158 $ 135 The change in noncontrolling interest for the three March 31, 2017 2016, 2017 2016 Balance at January 1 $ 937 $ 391 Acquisition of noncontrolling interest — (277 ) Balance at March 31 $ 937 $ 114 |
Note 8 - Significant Agreements
Note 8 - Significant Agreements | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 8. Research and Development Activities Firmenich Collaboration Agreement In March 2013, November 2010 10 3 twelve The Firmenich Collaboration Agreement provided for annual, up-front funding to the Company by Firmenich of $10.0 first three $10.0 March 2013, 2014 2015. $5.0 four March 2017, third $1.1 $3.0 three March 31, 2017 2016, six, six, Under the Firmenich Collaboration Agreement, the parties agreed to jointly select target compounds, subject to final approval of compound specifications by Firmenich. During the development phase, the Company would be required to provide labor, intellectual property and technology infrastructure and Firmenich would be required to contribute downstream polishing expertise and market access. The Firmenich Collaboration Agreement provides that the Company will own research and development and strain engineering intellectual property, and Firmenich will own blending and, if applicable, chemical conversion intellectual property. Under certain circumstances, such as the Company’s insolvency, Firmenich would gain expanded access to the Company’s intellectual property. The Firmenich Collaboration Agreement contemplates that, following development of flavors and fragrances compounds, the Company will manufacture the initial target molecules for the compounds and Firmenich will perform any required downstream polishing and distribution, sales and marketing. The Firmenich Collaboration Agreement provides that the parties will mutually agree on a supply price for each compound developed under the agreement and, subject to certain exceptions, will share product margins from sales of each such compound on a 70/30 (70% $15.0 50/50. one $2.5 In September 2014, $1.2 $2.0 three March 31, 2017 2016, In December 2016, third ten third Kuraray Collaboration Agreement In July 2011, March 2014, two $4.0 two $2.0 first April 30, 2014 second April 30, 2015. March 2015, December 31, 2016 second $2.0 March 31, 2015. November 2016 #3 December 31, 2018 $1.0 two $500,000 January 15, 2017 January 15, 2018, The Company recognized (i) collaboration revenues of $0.1 $0.4 three March 31, 2017 2016, $1.6 zero three March 31, 2017 2016, DARPA Technology Investment Agreement In September 2015, 2015 five 2015 2015 2015 2015 $35.0 4 $15.5 four may, 2015 The Company recognized collaboration revenues of $1.0 $0.4 three March 31, 2017 2016, Nenter Supply Agreement In April 2016, December 31, 2020 5 July 1, 2020, The Company recognized $2.3 three March 31, 2017. Givaudan Agreements In February 2011, October 2015, $0.6 zero three March 31, 2017 2016, 5 2 three In June 2016, $12.0 $3.0 June 30, 2016. $3.0 June 30, 2016 December 29, 2016, Pursuant to the Givaudan Collaboration Agreement, the Company agreed to grant to Givaudan an exclusive license to the intellectual property that the Company generates under the agreement. Such license will include the rights to make, use and sell compounds in the active cosmetics and flavors fields, and is subject to certain ‘claw back’ rights by the Company if a compound is not commercialized by Givaudan during the term of the agreement. The Company also agreed to grant Givaudan non-exclusive rights to certain portions of the Company’s existing intellectual property in order to facilitate activities under the Givaudan Collaboration Agreement. Givaudan, on the other hand, agreed to grant the Company a non-exclusive license to the intellectual property that is generated under the Givaudan Collaboration Agreement. Such non-exclusive license will include the rights to make, use and sell compounds in all fields except active cosmetics and flavors. Subject to certain rights granted to a third third 2 The Company recognized collaboration revenues of $1.5 three March 31, 2017. Ginkgo Initial Strategic Partnership Agreement and Collaboration Agreement In June 2016, $20.0 two ten first $15.0 July 25, 2016. second $5.0 March 31, 2017. In addition, pursuant to the Initial Ginkgo Agreement, (i) the Company and Ginkgo agreed to pursue the negotiation and execution of a detailed definitive partnership and license agreement setting forth the terms of a commercial partnership and collaboration arrangement between the parties (Ginkgo Collaboration), (ii) the Company agreed to issue to Ginkgo an option to purchase five $0.50, one October 31, 2016 5, On August 6, 2016, five $0.50 one On September 30, 2016, third March 30, 2017, $5.0 March 31, 2017. $5.0 March 31, 2017. Under the Ginkgo Collaboration Agreement, subject to certain exceptions, including excluded or refused products and cost savings initiatives, the profit on the sale of products subject to the Ginkgo Collaboration Agreement as well as cost-sharing, milestone and “value-creation” payments associated with the development and production of such products will be shared equally between the parties. The parties also agreed to provide each other with a license and other rights to certain intellectual property necessary to support the development and manufacture of the products under the Ginkgo Collaboration, and also to provide each other with access to certain other intellectual property useful in connection with the activities to be undertaken under the Ginkgo Collaboration Agreement, subject to certain carve-outs. The initial term of the Ginkgo Collaboration Agreement is three one 90 18 30 The Company recognized zero three March 31, 2017. March 31, 2017, $3.0 (December 31, 2016, $1.6 Intellectual Property License and Strain Access Agreement with Blue California In December 2016, $10 March 31, 2017, 18 Financing Agreements At Market Issuance Sales Agreement On March 8, 2016, may $50.0 3 333 203216), April 15, 2015. 415 one may 3.0% During the three March 31, 2017, $50.0 LSA Amendment See Note 5, Fidelity Notes Exchange See Note 5, Amendment to March 2016 See Note 5, March 2016 |
Note 9 - Goodwill and Intangibl
Note 9 - Goodwill and Intangible Assets | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 9. The following table presents the components of the Company's intangible assets (in thousands): March 31, 2017 December 31, 2016 Useful Life Gross Accumulated Net Gross Accumulated Net In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (8,560 ) $ — Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (9,332 ) $ 560 The in-process research and development (IPR&D) of $8.6 October 2011 2015. The Company has a single reportable segment (see Note 15, |
Note 10 - Stockholders' Deficit
Note 10 - Stockholders' Deficit | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 10. Unexercised Common Stock Warrants As of March 31, 2017 2016, 14,663,411 7,328,069, $0.01 $10.67 5.1 |
Note 11 - Stock-based Compensat
Note 11 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 11. The Company’s stock option activity and related information for the three March 31, 2017 Number Weighted- Weighted- Aggregate (in thousands) Outstanding - December 31, 2016 13,487,685 $ 3.63 6.70 $ 443 Options granted 726,000 $ 0.58 — — Options exercised (500 ) $ 0.28 — — Options cancelled (695,912 ) $ 1.82 — — Outstanding - March 31, 2017 13,517,273 $ 3.55 6.83 $ 44 Vested and expected to vest after March 31, 2017 12,347,493 $ 3.79 6.63 $ 38 Exercisable at March 31, 2017 7,478,686 $ 5.42 5.28 $ 1 The aggregate intrinsic value of options exercised under all option plans was zero three March 31, 2017 2016, The Company’s restricted stock units (or "RSUs") and restricted stock activity and related information for the three March 31, 2017 RSUs Weighted- Weighted Average Outstanding - December 31, 2016 6,997,084 $ 1.18 1.44 Awarded 825,980 $ 0.59 — Vested (348,699 ) $ 1.28 — Forfeited (250,329 ) $ 1.03 — Outstanding - March 31, 2017 7,224,036 $ 1.11 1.39 Expected to vest after March 31, 2017 5,735,089 $ 1.15 1.17 The following table summarizes information about stock options outstanding as of March 31, 2017: Options Outstanding Options Exercisable Exercise Price Number of Options Weighted- Weighted-Average Number of Options Weighted-Average $0.28 — $0.58 795,734 9.48 $ 0.49 2,234 $ 0.28 $0.59 — $0.59 2,224,375 9.13 $ 0.59 — $ — $0.69 — $1.63 1,491,082 8.67 $ 1.30 361,067 $ 1.60 $1.64 — $1.96 2,192,975 7.51 $ 1.84 1,026,492 $ 1.83 $1.98 — $2.87 1,780,408 6.07 $ 2.69 1,579,154 $ 2.73 $2.96 — $3.44 688,795 6.40 $ 3.15 597,154 $ 3.13 $3.51 — $3.51 1,447,979 6.90 $ 3.51 1,057,049 $ 3.51 $3.55 — $4.31 1,723,976 3.31 $ 3.97 1,683,443 $ 3.98 $4.35 — $26.84 1,111,949 3.52 $ 17.71 1,111,949 $ 17.71 $30.17 — $30.17 60,000 3.96 $ 30.17 60,000 $ 30.17 $0.28 — $30.17 13,517,273 6.83 $ 3.55 7,478,686 $ 5.42 Stock-Based Compensation Expense Stock-based compensation expense related to options and restricted stock units granted to employees and nonemployees was allocated to research and development expense and sales, general and administrative expense as follows (in thousands): Three Months Ended March 31, 2017 2016 Research and development $ 484 $ 491 Sales, general and administrative 1,162 1,560 Total stock-based compensation expense $ 1,646 $ 2,051 As of March 31, 2017, $3.7 $4.7 2.71 2.58 Stock-based compensation expense for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. Stock-based compensation expense for stock options and employee stock purchase plan rights is estimated at the grant date and offering date, respectively, based on their fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions: Three Months Ended March 31, 2017 2016 Expected dividend yield — % — % Risk-free interest rate 2.1 % 1.4 % Expected term (in years) 6.15 6.23 Expected volatility 80 % 73 % Expected Dividend Yield Risk-Free Interest Rate Expected Term Expected Volatility Forfeiture Rate may Each of the inputs discussed above is subjective and generally requires significant management and director judgment. |
Note 12 - Employee Benefit Plan
Note 12 - Employee Benefit Plan | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Pension and Other Postretirement Benefits Disclosure [Text Block] | 12. The Company established a 401(k) may 401(k) 90% January 2014, 90% one three March 31, 2017 2016 $0.1 |
Note 13 - Related Party Transac
Note 13 - Related Party Transactions | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 13. Related Party Financings See Note 5, February 2016 March 2016 June 2016 October 2016 18, March 31, 2017. As of March 31, 2017 December 31, 2016, $73.9 $72.4 $6.0 $6.7 The fair value of the derivative liability related to the related party convertible notes as of March 31, 2017 December 31, 2016 $1.4 $0.8 $1.1 $4.5 three March 31, 2017 2016, 3, Related Party Revenues The Company recognized no related party revenues from product sales to Total for each of the three March 31, 2017 2016. March 31, 2017 December 31, 2016, $0.3 $0.8 October 2016 three March 31, 2017 December 31, 2016. Loans to Related Parties See Note 7, Joint Venture with Total In November 2013, 7, Pilot Plant Agreements In May 2014, April 4, 2014 five $0.9 July 2015, #1 $2.0 February 28, 2017, secondees August 1, 2012, February 28, 2017, secondees May 1, 2016, secondees $1.7 $2.2 March 31, 2017 December 31, 2016, As of March 31, 2017, $1.7 $0.0 $0.2 three March 31, 2017 2016, |
Note 14 - Income Taxes
Note 14 - Income Taxes | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 14. The Company recorded a benefit from income taxes of $0.04 three March 31, 2017 $0.1 three March 31, 2016. three March 31, 2017 2016 On December 15, 2011, 2008 2008, may |
Note 15 - Reporting Segments
Note 15 - Reporting Segments | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 15. The chief operating decision maker for the Company is the chief executive officer. The chief executive officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one Revenues by geography are based on the location of the customer. The following tables set forth revenue and long-lived assets by geographic area (in thousands): Revenues Three Months Ended March 31, 2017 2016 Europe $ 5,376 $ 4,372 United States 3,096 3,462 Asia 4,433 590 Brazil 19 375 Other 56 12 Total $ 12,980 $ 8,811 Long-Lived Assets (Property, Plant and Equipment) March 31, 2017 December 31, 2016 Brazil $ 39,137 $ 44,153 United States 13,683 9,342 Europe 225 240 Total $ 53,045 $ 53,735 |
Note 16 - Comprehensive Loss
Note 16 - Comprehensive Loss | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Comprehensive Income (Loss) Note [Text Block] | 16. Comprehensive loss represents all changes in stockholders’ deficit except those resulting from investments or contributions by stockholders. The Company’s foreign currency translation adjustments represent the components of comprehensive loss excluded from the Company’s net loss and have been disclosed in the condensed consolidated statements of comprehensive loss for the periods presented. The components of accumulated other comprehensive loss are as follows (in thousands): March 31, 2017 December 31, 2016 Foreign currency translation adjustment, net of tax $ (40,581 ) $ (40,904 ) Total accumulated other comprehensive loss $ (40,581 ) $ (40,904 ) |
Note 17 - Net Loss Attributable
Note 17 - Net Loss Attributable to Common Stockholders and Net Loss Per Share | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 17. The Company computes net loss per share in accordance with ASC 260, three March 31, 2017, The following table presents the calculation of basic and diluted net loss per share of common stock attributable to Amyris, Inc. common stockholders (in thousands, except share and per share amounts): Three Months Ended March 31, 2017 2016 Numerator: Net loss attributable to Amyris, Inc. common stockholders $ (37,371 ) $ (15,308 ) Interest on convertible debt — 1,817 Accretion of debt discount — 1,633 Gain from change in fair value of derivative instruments — (18,415 ) Net loss attributable to Amyris, Inc. common stockholders after assumed conversion $ (37,371 ) $ (30,273 ) Denominator: Weighted average shares of common stock outstanding for basic EPS 290,039,216 207,199,563 Basic and diluted loss per share $ (0.13 ) $ (0.07 ) Weighted average shares of common stock outstanding 290,039,216 207,199,563 Effect of dilutive securities: Convertible promissory notes — 53,732,522 Weighted common stock equivalents — 53,732,522 Diluted weighted-average common shares 290,039,216 260,932,085 Diluted loss per share $ (0.13 ) $ (0.12 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock because including them would have been anti-dilutive: Three Months Ended March 31, 2017 2016 Period-end stock options to purchase common stock 13,517,273 12,159,154 Convertible promissory notes (1) 72,826,108 99,648,739 Period-end common stock warrants 5,021,087 5,885,762 Period-end restricted stock units 7,224,036 5,175,430 Total 98,588,504 122,869,085 ______________ (1) The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 18 - Subsequent Events
Note 18 - Subsequent Events | 3 Months Ended |
Mar. 31, 2017 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 18. Ginkgo Collaboration Note On April 13, 2017, $3 8, second October 27, 2016 April 13, 2017, April 13, 2017 13.50% May 15, 2017, may April 2017 On April 13, 2017, April 2017 $15.0 April 2017 $1.90 April 2017 April 2017 first third April 2017 April 2017 The April 2017 two April 17, 2017. April 2017 $7.0 second December 31, 2017, second April 2017 $8.0 The April 2017 April 2017 18 The April 2017 118% April 2017 April 2017 50% $200,000. The April 2017 may April 2017 118% In the event of a Fundamental Transaction (as defined in the April 2017 April 2017 may April 2017 118% The Company has the right to redeem the April 2017 118% April 2017 The April 2017 $1.90 Notwithstanding the foregoing, the holders will not have the right to convert any portion of an April 2017 4.99% 9.99%, 61 April 2017 54,676,770 April 2017 April 2017 April 2017 49,233,710 For as long as they hold April 2017 April 2017 may $1.05 April 2017 $1.00, may Amendment to Convertible Notes On May 2, 2017, April 2017 December 2016 April 2017 December 2016 April 2017 December 2016 April 2017 may 10% 20% 80% December 2016 April 2017 five 70% Blue California In April 2017, December 2016 one $10 December 2016. April 21, 2017, 850,115 May 2017 On May 8, 2017, May 2017 22,140 17.38% $0.0001 65,203.8756 17.38% $0.0001 $0.0001 207,954,414 May 2017 May 2017 May 2017 On May 11, 2017, May 2017 May 2017 May 2017 $44.5 May 2017 $22,140,000, May 2017 $25,000,000 $40.2 The May 2017 May 2017 may July 31, 2017 may one May 2017 Series A Preferred Stock Each share of Series A Preferred Stock has a stated value of $1,000 $1.15 90th Dividends, at a rate per year equal to 17.38% tenth October 15 April 15, October 15, 2017, tenth $1,738 $1,000 first Unless and until converted into common stock in accordance with its terms, the Series A Preferred Stock has no voting rights, other than as required by law or with respect to matters specifically affecting the Series A Preferred Stock. In the event of a fundamental transaction, the holders of the Series A Preferred Stock will have the right to receive the consideration receivable as a result of such fundamental transaction by a holder of the number of shares of Common Stock for which the Series A Preferred Stock is convertible immediately prior to such fundamental transaction (without regard to whether such Series A Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of Common Stock would receive if the Series A Preferred Stock were fully converted to Common Stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series A Preferred Stock is convertible at such time) , which amount shall be paid pari passu with all holders of Common Stock. Notwithstanding the foregoing, the holders (other than the Designated Holder (as defined below)) will not have the right to convert any Series A Preferred Stock, and the Company shall not effect any conversion of the Series A Preferred Stock, if the holder, together with its affiliates, would beneficially own in excess of 4.99% 9.99%, 61 On May 8, 2017, 17.38% Series B Preferred Stock The Series B Preferred Stock will have substantially identical terms to the Series A Preferred Stock (as described above), except that the issuance of the shares of common stock issuable upon conversion of the Series B Preferred Stock or as payment of dividends or the Make-Whole Payment on the Series B Preferred Stock (or the Series B Conversion Shares) will be subject to the Stockholder Approval (as defined below). The investors that purchased shares of the Series B Preferred Stock included existing stockholders of the Company affiliated with certain members of our Board of Directors (or the Affiliated Investors): Foris Ventures, LLC (Foris, an entity affiliated with director John Doerr of Kleiner Perkins Caufield & Byers, a current stockholder), which purchased 30,728.589 May 2017 73,160,764 2,333.216 May 2017 5,556,038 $27.0 February 12, 2016, June 24, 2016 October 21, 2016, 5, $2.0 February 12, 2016, 5, In addition, the investors that purchased shares of the Series B Preferred Stock included holders of certain of the Company’s existing indebtedness, including the 2014 144A 2015 144A 5, 2014 144A 2015 144A $3.4 2014 144A $3.7 2015 144A May 2017 May 2017 May 2017 The Series B Preferred Stock was issued in a private placement pursuant to the exemption from registration under Section 4(a)(2) On May 8, 2017, 17.38% May 2017 Pursuant to the May 2017 May 2017 $0.52 50% 103,977,207 $0.62 50% 103,977,207 three May 2017 In addition, at the May 2017 $0.0001 three May 2017 $0.42 May 2017 The exercise of the May 2017 May 2017 five The May 2017 4 (a)(2) Stockholder Approval Pursuant to the May 2017 May 2017 May 2017 July 10, 2017, 15 1 2017 May 23, 2017 July 10, 2017 May 2017 four May 2017 Registration Rights Pursuant to the May 2017 30 3 3 May 2017 181 May 2017 May 2017 144 Stockholder Agreement In connection with, and as a condition to, the May 2017 May 11, 2017, one 25,000 59,521,740 May 2017 $25,000,000. one 4.5% 60 2018. May 2017 Pursuant to the Stockholder Agreement, the Designated Holder agreed not to sell or transfer any of the shares of Series B Preferred Stock or May 2017 one May 2017 third first May 2017 May 2017 three 33% May 2017 13(d)(3) 1934) In addition, the Company has agreed to register, via one May 2017 180 May 2017 225th May 2017 may three 25% Pursuant to the Stockholder Agreement, the Company and the Designated Holder have agreed to negotiate in good faith during the 90 May 2017 $25 $30 90 second 90 December 31, 2017, first $5 Exchange In connection with the transactions contemplated by the May 2017 May 8, 2017, May 2017 20,920,578 20,920.578 $0.0001 May 2017 Series C Preferred Stock Each share of Series C Preferred Stock has a stated value of $1,000 1 $1 1 The Series C Preferred Stock will be entitled to participate with the common stock on an as-converted basis with respect to any dividends or other distributions to holders of common stock. The Series C Preferred Stock shall vote together as one In the event of a fundamental transaction, the holders of the Series C Preferred Stock will have the right to receive the consideration receivable as a result of such fundamental transaction by a holder of the number of shares of common stock for which the Series C Preferred Stock is convertible immediately prior to such fundamental transaction (without regard to whether such Series C Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of common stock. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series C Preferred stock shall be entitled to receive out of the assets of the Company an amount equal to the greater of (i) the par value of each share of Series C Preferred Stock, plus any accrued and unpaid dividends or other amounts due on such Series C Preferred Stock, prior to any distribution or payment to the holders of common stock or (ii) the amount that a holder would receive if the Series C Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series C Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. On May 8, 2017, The Series C Preferred Stock will be issued in a private exchange pursuant to the exemption from registration under Section 3(a)(9) Voting Agreements In connection with the transactions contemplated by the May 2017 51.2% April 30, 2017. Nenter Termination Agreement In connection with the transactions contemplated by the May 2017 May 8, 2017, October 26, 2016, $2.5 June 22, 2017. Temasek Letter Agreement On May 5, 2017, ($10.0 March 31, 2017) 5, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (or “GAAP”) and with the instructions for Form 10 10 December 31, 2016 April 17, 2017. The Company uses the equity method to account for investments in companies, if its investments provide it with the ability to exercise significant influence over operating and financial policies of the investee. Consolidated net income or loss includes the Company’s proportionate share of the net income or loss of these companies. Judgments made by the Company regarding the level of influence over each equity method investment include considering key factors such as the Company’s ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation The condensed consolidated financial statements of the Company include the accounts of Amyris, Inc., its subsidiaries and two 7, |
Consolidation, Variable Interest Entity, Policy [Policy Text Block] | Variable Interest Entities The Company has interests in joint venture entities that are VIEs. Determining whether to consolidate a VIE requires judgment in assessing (i) whether an entity is a VIE and (ii) if the Company is the entity’s primary beneficiary and thus required to consolidate the entity. To determine if the Company is the primary beneficiary of a VIE, the Company evaluates whether it has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company’s evaluation includes identification of significant activities and an assessment of its ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding and financing and other applicable agreements and circumstances. The Company’s assessment of whether it is the primary beneficiary of its VIEs requires significant assumptions and judgment. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates In preparing the unaudited condensed consolidated financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, except for the impact of adoption of certain accounting standards as described below, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the quarter ended March 31, 2017 2015 11, Simplifying the Measurement of Inventory 2016 06, Contingent Put and Call Options in Debt Instruments 2016 09, Compensation - Stock Compensation (Topic 718): The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In November 2016, 2016 18 Statement of Cash Flows - Restricted Cash. December 15, 2017, In October 2016, 2016 16, Intra-Entity Transfers of Assets Other Than Inventory December 15, 2017. first 2017. In August 2016, 2016 15 Classification of Certain Cash Receipts and Cash Payments December 15, 2017 In June 2016, 2016 13, Allowance for Loan and Lease Losses (Financial Instruments - Credit Losses Topic 326) December 15, 2019, December 15, 2018, In February 2016, Update2016 02 Leases December 15, 2018. may In January 2016, 2016 01 Financial Instruments-Overall December 15, 2017, In May 2014, March, April, May December 2016, 2016 08); 2016 10) 2016 12). July 9, 2015, one December 15, 2017 December 15, 2016. March 31, 2018. may |
Note 3 - Fair Value of Financ27
Note 3 - Fair Value of Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 297 $ — $ — $ 297 Certificates of deposit 1,188 — — 1,188 Total financial assets $ 1,485 $ — $ — $ 1,485 Financial Liabilities Loans payable (1) $ — $ 51,378 $ — $ 51,378 Credit facilities (1) — 50,891 — 50,891 Convertible notes (1) — — 115,268 115,268 Compound embedded derivative liabilities — — 2,728 2,728 Currency interest rate swap derivative liability — 2,961 — 2,961 Total financial liabilities $ — $ 105,230 $ 117,996 $ 223,226 Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,373 — — 1,373 Total financial assets $ 2,922 $ — $ — $ 2,922 Financial Liabilities Loans payable (1) $ — $ 53,579 $ — $ 53,579 Credit facilities (1) — 51,261 — 51,261 Convertible notes (1) — — 117,767 117,767 Compound embedded derivative liabilities — — 4,135 4,135 Currency interest rate swap derivative liability — 3,343 — 3,343 Total financial liabilities $ — $ 108,183 $ 121,902 $ 230,085 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | 2017 Balance at January 1 $ 117,767 New instruments 15,049 Conversion/extinguishment of convertible notes (21,077 ) Change in fair value of convertible notes 3,529 Balance at March 31 $ 115,268 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | 2017 Balance at January 1 $ 4,135 Gain from change in fair value of derivative liabilities (1,984 ) Additions 577 Balance at March 31 $ 2,728 |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] | March 31, 2017 March 31, 2016 Risk-free interest rate 0.74% - 1.30% 0.80% - 0.89% Risk-adjusted yields 12.50% - 22.63% 35.00% - 45.13% Stock-price volatility 45% 45% Probability of change in control 5% 5% Stock price $0.53 $1.11 Credit spread 11.28% - 21.35% 34.16% - 44.25% Estimated conversion dates 2017 - 2019 2016 - 2019 |
Derivative Instruments, Gain (Loss) [Table Text Block] | Type of Derivative Income Three Months Ended March 31, 2017 2016 Currency interest rate swap Gain from change in fair value of derivative instruments $ 355 $ 845 |
Schedule of Derivative Liabilities at Fair Value [Table Text Block] | March 31, December 31, Fair market value of compound embedded derivative liabilities $ 2,150 $ 4,135 Non-current fair value of swap obligations 2,979 3,343 Total derivative liabilities $ 5,129 $ 7,478 |
Note 4 - Balance Sheet Compon28
Note 4 - Balance Sheet Components (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | March 31, December 31, Raw materials $ 3,038 $ 3,159 Work-in-process 1,343 1,848 Finished goods 2,696 1,206 Inventories, net $ 7,077 $ 6,213 |
Property, Plant and Equipment [Table Text Block] | March 31, December 31, Machinery and equipment $ 84,853 $ 82,688 Leasehold improvements 38,828 38,785 Computers and software 9,658 9,585 Buildings 4,834 4,699 Furniture and office equipment 2,350 2,333 Vehicles 136 164 Land 460 460 Construction in progress 2,465 2,216 143,584 140,930 Less: accumulated depreciation and amortization (90,539 ) (87,195 ) Property, plant and equipment, net $ 53,045 $ 53,735 |
Schedule of Other Assets, Noncurrent [Table Text Block] | March 31, December 31, Recoverable taxes from Brazilian government entities $ 14,894 $ 13,723 Deposits on property and equipment, including taxes 499 291 Other 1,401 1,450 Total other assets $ 16,794 $ 15,464 |
Schedule of Accrued and Other Current Liabilities [Table Text Block] | March 31, December 31, Withholding tax related to conversion of related party notes $ 1,370 $ 1,370 Professional services 5,358 6,876 SMA relocation accrual 3,746 3,641 Accrued interest 8,259 4,847 Tax-related liabilities 2,480 2,610 Accrued vacation 2,228 2,034 Payroll and related expenses 2,761 4,310 Deferred rent, current portion 1,111 1,111 Contractual obligations to contract manufacturers 381 — Other 1,960 2,389 Total accrued and other current liabilities $ 29,654 $ 29,188 |
Note 5 - Debt and Mezzanine E29
Note 5 - Debt and Mezzanine Equity (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | March 31, 2017 December 31, 2016 Senior secured loan facility $ 27,844 $ 27,658 BNDES credit facility 904 1,172 FINEP credit facility 637 696 Guanfu credit facility 19,858 19,564 Total credit facilities 49,243 49,090 Convertible notes 75,218 78,981 Related party convertible notes 43,335 42,754 Related party loan payable 30,554 29,691 Loans payable 22,588 26,527 Total debt 220,938 227,043 Less: current portion (49,455 ) (59,155 ) Long-term debt $ 171,483 $ 167,888 Mezzanine equity $ 5,000 $ 5,000 |
Schedule of Long-term Debt Instruments [Table Text Block] | Years ending December 31: Related Party Convertible Loans Related Credit Total 2017 (remaining nine months) $ 4,537 $ 12,677 $ 11,899 $ 31,511 $ 5,271 $ 65,895 2018 16,290 21,803 2,878 — 33,710 74,681 2019 34,913 93,287 2,766 — 2,580 133,546 2020 — — 2,656 — 2,500 5,156 2021 — — 2,543 — 27,396 29,939 Thereafter — — 1,442 — — 1,442 Total future minimum payments (1) 55,740 127,767 24,184 31,511 71,457 310,659 Less: amount representing interest (2) (12,405 ) (52,549 ) (1,596 ) (957 ) (22,214 ) (89,721 ) Present value of minimum debt payments 43,335 75,218 22,588 30,554 49,243 220,938 Less: current portion (3,611 ) (2,288 ) (11,780 ) (30,554 ) (1,222 ) (49,455 ) Noncurrent portion of debt $ 39,724 $ 72,930 $ 10,808 $ — $ 48,021 $ 171,483 |
Note 6 - Commitments and Cont30
Note 6 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block] | Years ending December 31: Capital Operating Total Lease 2017 (remaining nine months) $ 734 $ 5,194 $ 5,928 2018 106 6,909 7,015 2019 9 6,782 6,791 2020 — 7,012 7,012 2021 — 7,248 7,248 Thereafter — 10,993 10,993 Total future minimum lease payments 849 $ 44,138 $ 44,987 Less: amount representing interest (39 ) Present value of minimum lease payments 810 Less: current portion (405 ) Long-term portion $ 405 |
Note 7 - Joint Ventures and N31
Note 7 - Joint Ventures and Noncontrolling Interest (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Variable Interest Entities [Table Text Block] | (In thousands) March 31, December 31, Assets $ 2,306 $ 2,277 Liabilities $ 158 $ 135 |
Noncontrolling Interest [Table Text Block] | 2017 2016 Balance at January 1 $ 937 $ 391 Acquisition of noncontrolling interest — (277 ) Balance at March 31 $ 937 $ 114 |
Note 9 - Goodwill and Intangi32
Note 9 - Goodwill and Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Intangible Assets and Goodwill [Table Text Block] | March 31, 2017 December 31, 2016 Useful Life Gross Accumulated Net Gross Accumulated Net In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (8,560 ) $ — Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (9,332 ) $ 560 |
Note 11 - Stock-based Compens33
Note 11 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block] | Number Weighted- Weighted- Aggregate (in thousands) Outstanding - December 31, 2016 13,487,685 $ 3.63 6.70 $ 443 Options granted 726,000 $ 0.58 — — Options exercised (500 ) $ 0.28 — — Options cancelled (695,912 ) $ 1.82 — — Outstanding - March 31, 2017 13,517,273 $ 3.55 6.83 $ 44 Vested and expected to vest after March 31, 2017 12,347,493 $ 3.79 6.63 $ 38 Exercisable at March 31, 2017 7,478,686 $ 5.42 5.28 $ 1 |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | RSUs Weighted- Weighted Average Outstanding - December 31, 2016 6,997,084 $ 1.18 1.44 Awarded 825,980 $ 0.59 — Vested (348,699 ) $ 1.28 — Forfeited (250,329 ) $ 1.03 — Outstanding - March 31, 2017 7,224,036 $ 1.11 1.39 Expected to vest after March 31, 2017 5,735,089 $ 1.15 1.17 |
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | Options Outstanding Options Exercisable Exercise Price Number of Options Weighted- Weighted-Average Number of Options Weighted-Average $0.28 — $0.58 795,734 9.48 $ 0.49 2,234 $ 0.28 $0.59 — $0.59 2,224,375 9.13 $ 0.59 — $ — $0.69 — $1.63 1,491,082 8.67 $ 1.30 361,067 $ 1.60 $1.64 — $1.96 2,192,975 7.51 $ 1.84 1,026,492 $ 1.83 $1.98 — $2.87 1,780,408 6.07 $ 2.69 1,579,154 $ 2.73 $2.96 — $3.44 688,795 6.40 $ 3.15 597,154 $ 3.13 $3.51 — $3.51 1,447,979 6.90 $ 3.51 1,057,049 $ 3.51 $3.55 — $4.31 1,723,976 3.31 $ 3.97 1,683,443 $ 3.98 $4.35 — $26.84 1,111,949 3.52 $ 17.71 1,111,949 $ 17.71 $30.17 — $30.17 60,000 3.96 $ 30.17 60,000 $ 30.17 $0.28 — $30.17 13,517,273 6.83 $ 3.55 7,478,686 $ 5.42 |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Three Months Ended March 31, 2017 2016 Research and development $ 484 $ 491 Sales, general and administrative 1,162 1,560 Total stock-based compensation expense $ 1,646 $ 2,051 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Three Months Ended March 31, 2017 2016 Expected dividend yield — % — % Risk-free interest rate 2.1 % 1.4 % Expected term (in years) 6.15 6.23 Expected volatility 80 % 73 % |
Note 15 - Reporting Segments (T
Note 15 - Reporting Segments (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] | Three Months Ended March 31, 2017 2016 Europe $ 5,376 $ 4,372 United States 3,096 3,462 Asia 4,433 590 Brazil 19 375 Other 56 12 Total $ 12,980 $ 8,811 |
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] | March 31, 2017 December 31, 2016 Brazil $ 39,137 $ 44,153 United States 13,683 9,342 Europe 225 240 Total $ 53,045 $ 53,735 |
Note 16 - Comprehensive Loss (T
Note 16 - Comprehensive Loss (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | March 31, 2017 December 31, 2016 Foreign currency translation adjustment, net of tax $ (40,581 ) $ (40,904 ) Total accumulated other comprehensive loss $ (40,581 ) $ (40,904 ) |
Note 17 - Net Loss Attributab36
Note 17 - Net Loss Attributable to Common Stockholders and Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended March 31, 2017 2016 Numerator: Net loss attributable to Amyris, Inc. common stockholders $ (37,371 ) $ (15,308 ) Interest on convertible debt — 1,817 Accretion of debt discount — 1,633 Gain from change in fair value of derivative instruments — (18,415 ) Net loss attributable to Amyris, Inc. common stockholders after assumed conversion $ (37,371 ) $ (30,273 ) Denominator: Weighted average shares of common stock outstanding for basic EPS 290,039,216 207,199,563 Basic and diluted loss per share $ (0.13 ) $ (0.07 ) Weighted average shares of common stock outstanding 290,039,216 207,199,563 Effect of dilutive securities: Convertible promissory notes — 53,732,522 Weighted common stock equivalents — 53,732,522 Diluted weighted-average common shares 290,039,216 260,932,085 Diluted loss per share $ (0.13 ) $ (0.12 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended March 31, 2017 2016 Period-end stock options to purchase common stock 13,517,273 12,159,154 Convertible promissory notes (1) 72,826,108 99,648,739 Period-end common stock warrants 5,021,087 5,885,762 Period-end restricted stock units 7,224,036 5,175,430 Total 98,588,504 122,869,085 |
Note 1 - The Company (Details T
Note 1 - The Company (Details Textual) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017USD ($) | Dec. 31, 2016USD ($) | |
Number of Operating Segments | 1 | |
Working Capital | $ (77,600) | |
Retained Earnings (Accumulated Deficit) | (1,171,809) | $ (1,134,438) |
Cash, Cash Equivalents, and Short-term Investments | 2,500 | |
Debt Instrument, Unamortized Discount | 42,000 | |
Long-term Debt | 220,938 | 227,043 |
Long-term Debt, Current Maturities, Including Due to Related Parties | 49,455 | $ 59,155 |
Interest Payable | $ 20,800 |
Note 2 - Summary of Significa38
Note 2 - Summary of Significant Accounting Policies (Details Textual) | 3 Months Ended |
Mar. 31, 2017 | |
Variable Interest Entity, Number of Entities | 2 |
Note 3 - Fair Value of Financ39
Note 3 - Fair Value of Financial Instruments (Details Textual) $ in Thousands, BRL in Millions | Mar. 31, 2017USD ($) | Mar. 31, 2017BRL | Dec. 31, 2016USD ($) |
Banco Pine July 2012 Loan Agreement [Member] | Interest Rate Swap [Member] | |||
Derivative, Notional Amount | $ 6,900 | BRL 22 | |
Derivative, Fixed Interest Rate | 3.94% | 3.94% | |
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | |||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ 2,728 | $ 4,135 | |
Derivative Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | |||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ 2,700 | $ 4,100 |
Note 3 - Fair Value of Financ40
Note 3 - Fair Value of Financial Instruments - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 | ||
Money market funds | $ 297 | $ 1,549 | ||
Certificates of deposit | 1,188 | 1,373 | ||
Total financial assets | 1,485 | 2,922 | ||
Loans payable | 51,378 | [1] | 53,579 | [2] |
Credit facilities | 50,891 | [1] | 51,261 | [2] |
Convertible notes | 115,268 | [1] | 117,767 | [2] |
Compound embedded derivative liabilities | 2,728 | 4,135 | ||
Currency interest rate swap derivative liability | 2,961 | 3,343 | ||
Total financial liabilities | 223,226 | 230,085 | ||
Fair Value, Inputs, Level 1 [Member] | ||||
Money market funds | 297 | 1,549 | ||
Certificates of deposit | 1,188 | 1,373 | ||
Total financial assets | 1,485 | 2,922 | ||
Loans payable | [1] | [2] | ||
Credit facilities | [1] | [2] | ||
Convertible notes | [1] | [2] | ||
Compound embedded derivative liabilities | ||||
Currency interest rate swap derivative liability | ||||
Total financial liabilities | ||||
Fair Value, Inputs, Level 2 [Member] | ||||
Money market funds | ||||
Certificates of deposit | ||||
Total financial assets | ||||
Loans payable | 51,378 | [1] | 53,579 | [2] |
Credit facilities | 50,891 | [1] | 51,261 | [2] |
Convertible notes | [1] | [2] | ||
Compound embedded derivative liabilities | ||||
Currency interest rate swap derivative liability | 2,961 | 3,343 | ||
Total financial liabilities | 105,230 | 108,183 | ||
Fair Value, Inputs, Level 3 [Member] | ||||
Money market funds | ||||
Certificates of deposit | ||||
Total financial assets | ||||
Loans payable | [1] | [2] | ||
Credit facilities | [1] | [2] | ||
Convertible notes | 115,268 | [1] | 117,767 | [2] |
Compound embedded derivative liabilities | 2,728 | 4,135 | ||
Currency interest rate swap derivative liability | ||||
Total financial liabilities | $ 117,996 | $ 121,902 | ||
[1] | These liabilities are carried on the condensed consolidated balance sheet on a historical cost basis. | |||
[2] | These liabilities are carried on the condensed consolidated balance sheet on a historical cost basis (noting that the Remaining Notes subject to the Maturity Treatment Agreement were revalued to fair value on July 29, 2015, see Note 5 "Debt and Mezzanine Equity" and Note 18, "Subsequent Events" for details). |
Note 3 - Fair Value of Financ41
Note 3 - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Fair Value, Inputs, Level 3 [Member] - Convertible Debt [Member] $ in Thousands | 3 Months Ended |
Mar. 31, 2017USD ($) | |
Balance, convertible notes | $ 117,767 |
New instruments | 15,049 |
Conversion/extinguishment of convertible notes | (21,077) |
Change in fair value of convertible notes | 3,529 |
Balance, convertible notes | $ 115,268 |
Note 3 - Fair Value of Financ42
Note 3 - Fair Value of Financial Instruments - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Liability, Compound Embedded Derivatives [Member] $ in Thousands | 3 Months Ended |
Mar. 31, 2017USD ($) | |
Balance, convertible notes | $ 4,135 |
Gain from change in fair value of derivative liabilities | (1,984) |
Additions | 577 |
Balance, convertible notes | $ 2,728 |
Note 3 - Fair Value of Financ43
Note 3 - Fair Value of Financial Instruments - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Risk-free interest rate | ||
Risk-adjusted yields | ||
Expected volatility | 45.00% | 45.00% |
Probability of change in control | 5.00% | 5.00% |
Stock price (in dollars per share) | $ 0.53 | $ 1.11 |
Credit spread | ||
Estimated conversion dates | ||
Minimum [Member] | ||
Risk-free interest rate | 0.74% | 0.80% |
Risk-adjusted yields | 12.50% | 35.00% |
Credit spread | 11.28% | 34.16% |
Estimated conversion dates | 2,017 | 2,016 |
Maximum [Member] | ||
Risk-free interest rate | 1.30% | 0.89% |
Risk-adjusted yields | 22.63% | 45.13% |
Credit spread | 21.35% | 44.25% |
Estimated conversion dates | 2,019 | 2,019 |
Note 3 - Fair Value of Financ44
Note 3 - Fair Value of Financial Instruments - Derivative Instruments Classification (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Currency Interest Rate Swap [Member] | Not Designated as Hedging Instrument [Member] | Gain (Loss) From Change in Fair Value of Derivative Instruments [Member] | ||
Currency interest rate swap | $ 355 | $ 845 |
Note 3 - Fair Value of Financ45
Note 3 - Fair Value of Financial Instruments - Derivative Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Fair market value of compound embedded derivative liabilities | $ 2,150 | $ 4,135 |
Non-current fair value of swap obligations | 2,979 | 3,343 |
Total derivative liabilities | $ 5,129 | $ 7,478 |
Note 4 - Balance Sheet Compon46
Note 4 - Balance Sheet Components (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2017 | Mar. 31, 2016 | Dec. 31, 2016 | |
Property, Plant and Equipment, Gross | $ 143,584 | $ 140,930 | |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 90,539 | 87,195 | |
Depreciation, Depletion and Amortization | 2,715 | $ 2,869 | |
Property, Plant and Equipment, Including Capital Leases [Member] | |||
Depreciation, Depletion and Amortization | 2,700 | $ 2,900 | |
Capital Lease Obligations [Member] | |||
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 100 | 600 | |
Capital Lease Obligations [Member] | Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member] | |||
Property, Plant and Equipment, Gross | $ 3,100 | $ 3,100 |
Note 4 - Balance Sheet Compon47
Note 4 - Balance Sheet Components - Inventory, Current (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Raw materials | $ 3,038 | $ 3,159 |
Work-in-process | 1,343 | 1,848 |
Finished goods | 2,696 | 1,206 |
Inventories, net | $ 7,077 | $ 6,213 |
Note 4 - Balance Sheet Compon48
Note 4 - Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Property, plant and equipment | $ 143,584 | $ 140,930 |
Less: accumulated depreciation and amortization | (90,539) | (87,195) |
Property, plant and equipment, net | 53,045 | 53,735 |
Machinery and Equipment [Member] | ||
Property, plant and equipment | 84,853 | 82,688 |
Leasehold Improvements [Member] | ||
Property, plant and equipment | 38,828 | 38,785 |
Computer Equipment and Software [Member] | ||
Property, plant and equipment | 9,658 | 9,585 |
Building [Member] | ||
Property, plant and equipment | 4,834 | 4,699 |
Furniture and Fixtures [Member] | ||
Property, plant and equipment | 2,350 | 2,333 |
Vehicles [Member] | ||
Property, plant and equipment | 136 | 164 |
Land [Member] | ||
Property, plant and equipment | 460 | 460 |
Construction in Progress [Member] | ||
Property, plant and equipment | $ 2,465 | $ 2,216 |
Note 4 - Balance Sheet Compon49
Note 4 - Balance Sheet Components - Other Assets, Noncurrent (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Recoverable taxes from Brazilian government entities | $ 14,894 | $ 13,723 |
Deposits on property and equipment, including taxes | 499 | 291 |
Other | 1,401 | 1,450 |
Total other assets | $ 16,794 | $ 15,464 |
Note 4 - Balance Sheet Compon50
Note 4 - Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Withholding tax related to conversion of related party notes | $ 1,370 | $ 1,370 |
Professional services | 5,358 | 6,876 |
SMA relocation accrual | 3,746 | 3,641 |
Accrued interest | 8,259 | 4,847 |
Tax-related liabilities | 2,480 | 2,610 |
Accrued vacation | 2,228 | 2,034 |
Payroll and related expenses | 2,761 | 4,310 |
Deferred rent, current portion | 1,111 | 1,111 |
Contractual obligations to contract manufacturers | 381 | |
Other | 1,960 | 2,389 |
Total accrued and other current liabilities | $ 31,806 | $ 29,188 |
Note 5 - Debt and Mezzanine E51
Note 5 - Debt and Mezzanine Equity (Details Textual) $ / shares in Units, BRL in Millions | May 15, 2017USD ($) | May 11, 2017USD ($) | May 08, 2017USD ($) | Jan. 11, 2017USD ($) | Dec. 28, 2016USD ($) | Dec. 02, 2016USD ($) | Oct. 27, 2016USD ($) | Oct. 26, 2016USD ($) | Oct. 21, 2016USD ($) | Jun. 24, 2016USD ($) | May 10, 2016USD ($) | Feb. 15, 2016USD ($)$ / sharesshares | Feb. 12, 2016USD ($)$ / sharesshares | Feb. 12, 2016EUR (€) | Dec. 02, 2015USD ($) | Nov. 30, 2015USD ($) | Oct. 20, 2015USD ($) | Oct. 14, 2015USD ($)$ / sharesshares | Jul. 29, 2015USD ($)$ / sharesshares | Apr. 02, 2015 | Aug. 01, 2013 | Feb. 28, 2017USD ($) | Jan. 31, 2017USD ($) | Dec. 31, 2016USD ($)$ / shares | Mar. 31, 2016USD ($)$ / sharesshares | Mar. 31, 2016EUR (€) | Feb. 29, 2016USD ($)$ / sharesshares | Nov. 30, 2015USD ($) | Jul. 31, 2015USD ($)$ / sharesshares | Jun. 30, 2014USD ($) | May 31, 2014USD ($)$ / shares | Mar. 31, 2014USD ($) | Jan. 31, 2014USD ($)$ / shares | Dec. 31, 2013USD ($) | Oct. 31, 2013USD ($)$ / shares | Aug. 31, 2013USD ($)$ / sharesshares | Jul. 31, 2012USD ($) | Dec. 31, 2011BRL | Nov. 30, 2010 | Mar. 31, 2017USD ($)$ / sharesshares | Mar. 31, 2017BRL | Mar. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / shares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / shares | Dec. 31, 2015USD ($) | May 02, 2017$ / shares | Mar. 31, 2017BRLshares | Dec. 31, 2016BRL | Dec. 19, 2016USD ($) | Dec. 01, 2016USD ($)$ / shares | Sep. 30, 2016USD ($) | Sep. 30, 2016BRL | Sep. 02, 2016USD ($) | May 31, 2016shares | May 30, 2016USD ($)$ / shares | Feb. 28, 2016shares | Feb. 24, 2016 | Feb. 16, 2016$ / shares | Oct. 31, 2015USD ($) | Jun. 30, 2015 | Mar. 31, 2015USD ($) | Jan. 31, 2015USD ($)$ / shares | Jul. 31, 2014USD ($)$ / shares | Apr. 30, 2014USD ($)$ / shares | Oct. 04, 2013 | Sep. 30, 2013USD ($)shares | Jul. 31, 2013USD ($)$ / shares | Jun. 30, 2013USD ($)$ / shares | Mar. 31, 2013$ / shares | Sep. 14, 2012USD ($)$ / shares | Jul. 31, 2012BRL | Jul. 30, 2012USD ($) | Jun. 30, 2012USD ($) | Feb. 28, 2012USD ($)$ / shares |
Repayments of Long-term Debt | $ 4,273,000 | $ 729,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | 1,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 4,200,000 | $ 96,000 | $ (216,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 10.67 | $ 0.01 | $ 10.67 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 42,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years 36 days | 5 years 36 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | shares | 7,328,069 | 14,663,411 | 7,328,069 | 14,663,411 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 227,043,000 | $ 220,938,000 | $ 227,043,000 | $ 227,043,000 | $ 227,043,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letters of Credit Outstanding, Amount | $ 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Cash and Cash Equivalents, Noncurrent | 957,000 | 958,000 | 957,000 | 957,000 | 957,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Two Years | $ 74,681,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exchange Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JVCO Joint Venture [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 40,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | JVCO Joint Venture [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Percentage Investment Sold | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage by Counterparty | 75.00% | 75.00% | 75.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 19,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Exchange Ratio of Converted Debt to Original Debt | 1.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | $ 19,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (9,400,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | 42,800,000 | 43,300,000 | 42,800,000 | 42,800,000 | 42,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Discount, Related Party | 5,400,000 | 5,600,000 | 5,400,000 | 5,400,000 | 5,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | 42,754,000 | 43,335,000 | 42,754,000 | 42,754,000 | 42,754,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Two Years | 16,290,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | The Second Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 1 year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.87 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price | 60 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued, Rate Applicable to the First 180 Days | 13.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued Thereafter | 16.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued for Defaults | 12.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period | 180 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Exchanged and Cancelled | $ 6,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Period | 3 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | 17,300,000 | 17,600,000 | 17,300,000 | 17,300,000 | 17,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Discount, Related Party | 7,400,000 | 7,100,000 | 7,400,000 | 7,400,000 | 7,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Loan Facility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 27,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Issuance Costs, Line of Credit Arrangements, Net | 700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BNDES Credit Facility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 1,200,000 | 900,000 | 1,200,000 | 1,200,000 | 1,200,000 | BRL 2.9 | BRL 3.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | BRL 22.4 | 7,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 7.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Number of Monthly Installments | 60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | 0.10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | BRL 24.9 | 7,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility Bank Guarantee Percentage | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guarantor Obligations, Liquidation Proceeds, Percentage | 130.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BNDES Credit Facility [Member] | First Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | BRL | BRL 19.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BNDES Credit Facility [Member] | The Second Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | BRL | BRL 3.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility Bank Guarantee Percentage | 90.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Borrowings Above Which is New Tranche | BRL | BRL 19.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINEP Credit Facility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 700,000 | $ 700,000 | 700,000 | 700,000 | 700,000 | BRL 2 | BRL 2.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 2,000,000 | BRL 6.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Number of Monthly Installments | 81 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DebtDefualtPenaltyAndFineOnObligationInDefaultPercentage | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Interest On Late Balance Percentage Per Month | 1.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINEP Credit Facility [Member] | Threshold Met [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 11.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | € | € 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letter of Credit [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Cash and Cash Equivalents, Noncurrent | $ 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,000,000 | $ 18,000,000 | $ 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Unsecured Promissory Notes, 2016 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | $ 18,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 285,714 | 2,571,428 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Stegodon [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount, Current | 425,000 | 425,000 | 425,000 | 425,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount, Noncurrent | 450,000 | 450,000 | 450,000 | 450,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Stegodon [Member] | Ginkgo Collaboration Agreement [Member] | Senior Secured Loan Facility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Monies Agreed to Apply Toward Repayment of Outstanding Loans, Maximum | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Foris Ventures, LLC [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 16,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,285,714 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Guanfu Credit Agreement [Member] | Guanfu Holding Co., Ltd [Member] | Unsecured Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 25,000,000 | $ 25,000,000 | $ 25,000,000 | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage | 100.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Volume Weighted Average Closing Sale Price, Percentage | 90.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Volume Weighted Average Closing Sale Price, Number of Trading Days | 90 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading Days, Number of Days Proceeding Default | 2 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 7.0682 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 8,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | $ 9,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 2,165,898 | 2,165,898 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Acquisition Right Amount Redeemable, Percentage | 101.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Allowable Debt | $ 200,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Debt Percentage of Total Assets | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Amount of Secured Debt | $ 125,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets | 30.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Bridge Loan Amount, Convertible Promissory Note Covenants Waived | $ 35,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Consideration for Covenant Waiving, Convertible Promissory Notes | 7,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 3.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.74 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Offering | $ 75,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Convertible Note Offering | 15,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 72,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt Used to Repay Previously Issued Convertible Debt | $ 9,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Trading Days | 20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Consecutive Trading Days | 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Days for Conversion Notification | 5 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments | 0.75% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Percentage of Principal Repurchase Price | 100.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Affiliated Entity [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 18,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | 22,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amount of Convertible Debt Purchased by Affiliated Entities | $ 24,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Convertible Debt Securities [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 6.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Numerator [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Ratio | 267.037 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Denominator [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.25 | $ 1.41 | $ 1.41 | $ 1.41 | $ 1.41 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 38,415,626 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Allowable Debt | $ 200,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Amount of Secured Debt | $ 65,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets | 30.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 54,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | $ 1,000 | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments | 0.75% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Percentage of Principal Repurchase Price | 100.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Shares | shares | 443.6557 | 446.8707 | 711.1209 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Percentage of Average Price Per Share the Stock will be Valued upon Early Conversion | 92.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Trading Days Notes Become Convertible | 10 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Restrictions, Maximum Outstanding Debt | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 19,600,000 | $ 19,600,000 | $ 19,600,000 | $ 19,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | Subsequent Event [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Additional Principal Amount Issued During Period | $ 19,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 15,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 6.5% [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 18,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | 22,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 3% [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 8,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | $ 9,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage | 118.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 9,900,000 | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum Percentage | 19.99% | 19.99% | 19.99% | 19.99% | 19.99% | 19.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 10,000,000 | $ 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount, Contingent Second Closing | $ 5,000,000 | $ 5,000,000 | $ 5,000,000 | $ 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount | 50.00% | 50.00% | 50.00% | 50.00% | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock | $ 200,000 | $ 200,000 | $ 200,000 | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Length of Time from Date of Issuance, Threshold | 120 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions | 4.99% | 4.99% | 4.99% | 4.99% | 4.99% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions | 9.99% | 9.99% | 9.99% | 9.99% | 9.99% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice | 61 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holder Limitations, Maximum Sale Price Per Share of Common Stock | $ / shares | $ 1.05 | $ 1.05 | $ 1.05 | $ 1.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holders May Not Sell Shares, Price Floor, Threshold | $ / shares | $ 1 | $ 1 | $ 1 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | Threshold 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Price, Percentage upon Triggering Event | 112.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The December 2016 Convertible Note [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 9,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum Percentage | 19.99% | 19.99% | 19.99% | 19.99% | 19.99% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount | 50.00% | 50.00% | 50.00% | 50.00% | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock | $ 200,000 | $ 200,000 | $ 200,000 | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions | 4.99% | 4.99% | 4.99% | 4.99% | 4.99% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions | 9.99% | 9.99% | 9.99% | 9.99% | 9.99% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice | 61 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holder Limitations, Maximum Sale Price Per Share of Common Stock | $ / shares | $ 1.05 | $ 1.05 | $ 1.05 | $ 1.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Holders May Not Sell Shares, Price Floor, Threshold | $ / shares | $ 1 | $ 1 | $ 1 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Purchase Agreement [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 105,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 69,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 30,000,000 | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Initial Closing [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 7.0682 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Initial Closing [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.50% | 1.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | $ 38,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Installments | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Initial Closing [Member] | Total [Member] | New Funding [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 15,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Initial Closing [Member] | Total [Member] | Diesel Research and Development Funding [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 23,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Second Closing [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Second Closing [Member] | Total [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 20,000,000 | $ 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Installments | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Two Installments in Second Closing [Member] | Total [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 30,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Third Closing [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Third Closing [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,850,000 | $ 10,850,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Installments | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Two Installments In Third Closing [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 21,700,000 | $ 21,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2013 Letter Agreement [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.08 | $ 7.0682 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Closing Price Plus Incremental Rate | $ / shares | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Note [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
July 2012 Agreements [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,850,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 7.0682 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2014 Letter Agreement [Member] | Subsequent Event [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2014 Letter Agreement [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 75,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2014 Letter Agreement [Member] | Two Installments In Third Closing [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 4.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unsecured Promissory Notes, 2016 [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 1,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 2016 R&D Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Replacement Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | $ 3,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 1.50% | 1.50% | 1.50% | 1.50% | 1.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Allowable Debt | $ 200,000,000 | $ 200,000,000 | $ 200,000,000 | $ 200,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Debt Percentage of Total Assets | 50.00% | 50.00% | 50.00% | 50.00% | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Maximum Amount of Secured Debt | $ 125,000,000 | $ 125,000,000 | $ 125,000,000 | $ 125,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Secured Debt as a Percentage of Consolidated Total Assets | 30.00% | 30.00% | 30.00% | 30.00% | 30.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Default Rate | 2.50% | 2.50% | 2.50% | 2.50% | 2.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of Principal Amount of Notes, Required to Be Repaid in Change of Control | 101.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt | $ 3,700,000 | $ 3,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 13,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total [Member] | First Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 7,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total [Member] | Second Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | 5,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 73,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement Convertible Notes, Period | 2 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Number of Tranches | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | First Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 42,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | Second Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 30,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Temasek [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 35,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bridge Loan | $ 35,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Temasek [Member] | Second Tranche [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 110,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek Bridge Loan [Member] | Temasek [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (19,900,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 7,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 44,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Discount Percentage to Determine Conversion Price | 15.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price | 60 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Period After Which Convertible at the Option of Holder | 1 year 180 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plant Manufacturing Production, Product Sales, Percentage | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued, Rate Applicable to the First 180 Days | 6.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued Thereafter | 8.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued for Defaults | 6.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Period Over Which Interest is Payable in Kind | 2 years 180 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period | 180 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes, Initial Prepayment Term | 2 years 180 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 51,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 9,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 35,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Second Tranche [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Future Cancellation of Debt, Amount | $ 9,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 34,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | $ 6,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tranche I and Tranche II Notes [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 1.42 | $ 1.14 | $ 1.40 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt | $ 21,800,000 | $ 22,100,000 | $ 21,800,000 | $ 21,800,000 | $ 21,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,860,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Percentage of Principal Amount of Notes, Required to Be Repaid in Change of Control | 101.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tranche I and Tranche II Notes [Member] | Related Party Convertible Notes [Member] | Subsequent Event [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tranche I Notes [Member] | Temasek Funding Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,335,342 | 127,194 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tranche I Notes [Member] | Subsequent Event [Member] | Temasek Funding Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 16,886,320 | 16,886,320 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes 2016 [Member] | Subsequent Event [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 18,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2016 Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Foris Ventures, LLC [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt | $ 6,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 6,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Ginkgo Bioworks, Inc. [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt | $ 8,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 8,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Salisbury Note [Member] | Salisbury Partners, LLC [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,500,000 | $ 3,500,000 | $ 3,500,000 | $ 3,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty, Threshold | 5 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nikko Note [Member] | Nikko [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,900,000 | $ 3,900,000 | $ 3,900,000 | $ 3,900,000 | $ 3,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty, Threshold | 5 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Percentage of Joint Venture Interests Owned By the Company Securing the Debt Instrument | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Payments Required in Four Monthly Installments | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Equal Monthly Installments, Amount | 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aprinnova Notes [Member] | Aprinnova JV [Member] | Nikko [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.75% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 375,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nomis Bay Convertible Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt, Future Minimum Payments Due, Next Twelve Months | 3,900,000 | 3,900,000 | 3,900,000 | 3,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity Treatment Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Future Minimum Payments Due in Two Years | 46,800,000 | 46,800,000 | 46,800,000 | 46,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party and Non-Related Party Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 42,000,000 | $ 42,000,000 | $ 42,000,000 | $ 42,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TJLP Adjustment Factor [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DebtInstruementInterestRateOfTheCentralBankOfBrazilUsedAsAThreshold | 6.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TJLP Adjustment Factor [Member] | FINEP Credit Facility [Member] | Threshold Met [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Stock Price Trigger for Deferred Installments | $ / shares | $ 0.50 | $ 0.50 | $ 0.50 | $ 0.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Threshold Consecutive Trading Days, Deferred Installments | 5 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | March 2013 Letter Agreement [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 3.08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Stock Price Trigger for Deferred Installments | $ / shares | $ 1 | $ 1 | $ 1 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Threshold Consecutive Trading Days, Deferred Installments | 30 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loans Payable | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Prepayment Penalty, Percentage | 1.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Facility Charge, Percentage | 1.00% | 5.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, End of Term Fee, Percentage | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Forbearance Fee, Forgiven | $ 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Required Equity Financing, Amount | $ 50,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unencumbered, Unrestricted, Cash Required, Percentage | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 15,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Amount to be Raised Through Equity Triggering Withdrawal of the Credit Facility | $ 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Commitment Fee Percentage | 3.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Hercules Credit Additional Amount [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Amount Required | $ 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Third Hercules Amendment [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loans Payable | $ 31,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Long-term Debt | $ 10,960,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Long-term Debt | $ 9,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | 9.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | $ 767,200 | $ 767,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Third Hercules Amendment [Member] | Portion of Debt Costs Owed in Connection with Expired Facility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | 750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Third Hercules Amendment [Member] | Portion of Debt Costs Related to the Third Hercules Amendment [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | $ 250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Prime Rate [Member] | Third Hercules Amendment [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 6.25% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Minimum [Member] | Prime Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 6.25% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Minimum [Member] | Prime Rate [Member] | Hercules Credit Additional Amount [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5.25% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Maximum [Member] | Prime Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 9.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Maximum [Member] | Prime Rate [Member] | Hercules Credit Additional Amount [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 8.50% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nossa Caixa and Banco Pine Agreements [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $ 11,100,000 | $ 10,900,000 | $ 11,100,000 | $ 11,100,000 | $ 11,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | 5.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 16,400,000 | BRL 52 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | $ 21,500,000 | BRL 68 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Certain Farnesene Production Assets Pledged as Collateral for Loans | BRL | BRL 52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Period of Interest Only QuarterlyPayments | 2 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Banco Pine [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | BRL | 22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nossa Caixa [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | BRL | BRL 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,860,633 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant 1 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 14,677,861 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Numerator One | 30.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Denominator One | 69.40% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Numerator Two | 13.30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Denominator Two | 86.70% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Temasek Warrant Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Common Stock Shares Used In Calculation | shares | 880,339 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | shares | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | The 2013 Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,000,000 | 12,700,244 | 12,700,244 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | shares | 2,462,536 | 2,462,536 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | If Total R&D Warrant is Exercised in Full [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | shares | 2,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | If Total R&D Warrant is Exercised in Full [Member] | Temasek Warrant Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 880,339 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Common Stock Shares Used In Calculation | shares | 880,339 | 880,339 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Temasek [Member] | Rule 144A Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,434,782 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | € | € 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Total Funding Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 18,924,191 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Total R&D Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Temasek Warrant 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Unsecured Senior Convertible Promissory Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 1,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Tranche I and Tranche II Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 15,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total [Member] | Rule 144A Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 9,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total and Temasek [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 2.30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest Expense, Debt | $ 39,200,000 |
Note 5 - Debt and Mezzanine E52
Note 5 - Debt and Mezzanine Equity - Debt Components (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 | |
Debt | $ 220,938 | $ 227,043 | |
Less: current portion | (49,455) | (59,155) | |
Noncurrent portion of debt | 171,483 | 167,888 | |
Mezzanine equity | [1] | 5,000 | 5,000 |
Senior Secured Loan Facility [Member] | |||
Debt | 27,844 | 27,658 | |
BNDES Credit Facility [Member] | |||
Debt | 904 | 1,172 | |
FINEP Credit Facility [Member] | |||
Debt | 637 | 696 | |
Guanfu Credit Facility [Member] | |||
Debt | 19,858 | 19,564 | |
Credit Facility [Member] | |||
Debt | 49,243 | 49,090 | |
Noncurrent portion of debt | 48,021 | ||
Convertible Debt [Member] | |||
Debt | 75,218 | 78,981 | |
Noncurrent portion of debt | 72,930 | ||
Related Party Convertible Notes [Member] | |||
Debt | 43,335 | 42,754 | |
Noncurrent portion of debt | 39,724 | ||
Related Party Loan Payable [Member] | |||
Debt | 30,554 | 29,691 | |
Noncurrent portion of debt | |||
Loans Payable [Member] | |||
Debt | 22,588 | $ 26,527 | |
Noncurrent portion of debt | $ 10,808 | ||
[1] | See Note 8, "Significant Agreements" for details regarding the Bill & Melinda Gates Foundation Investment, classified as mezzanine equity. |
Note 5 - Debt and Mezzanine E53
Note 5 - Debt and Mezzanine Equity - Long-term Debt Instruments (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 | |
2017 (remaining nine months) | $ 65,895 | ||
Debt Future Minimum Payments Due in Two Years | 74,681 | ||
2,019 | 133,546 | ||
2,020 | 5,156 | ||
2,021 | 29,939 | ||
Thereafter | 1,442 | ||
Total future minimum payments(1) | [1] | 310,659 | |
Less: amount representing interest(2) | [2] | (89,721) | |
Present value of minimum debt payments | 220,938 | ||
Less: current portion | (49,455) | ||
Noncurrent portion of debt | 171,483 | $ 167,888 | |
Related Party Convertible Notes [Member] | |||
2017 (remaining nine months) | 4,537 | ||
Debt Future Minimum Payments Due in Two Years | 16,290 | ||
2,019 | 34,913 | ||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 55,740 | |
Less: amount representing interest(2) | [2] | (12,405) | |
Present value of minimum debt payments | 43,335 | ||
Less: current portion | (3,611) | ||
Noncurrent portion of debt | 39,724 | ||
Convertible Debt [Member] | |||
2017 (remaining nine months) | 12,677 | ||
Debt Future Minimum Payments Due in Two Years | 21,803 | ||
2,019 | 93,287 | ||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 127,767 | |
Less: amount representing interest(2) | [2] | (52,549) | |
Present value of minimum debt payments | 75,218 | ||
Less: current portion | (2,288) | ||
Noncurrent portion of debt | 72,930 | ||
Loans Payable [Member] | |||
2017 (remaining nine months) | 11,899 | ||
Debt Future Minimum Payments Due in Two Years | 2,878 | ||
2,019 | 2,766 | ||
2,020 | 2,656 | ||
2,021 | 2,543 | ||
Thereafter | 1,442 | ||
Total future minimum payments(1) | [1] | 24,184 | |
Less: amount representing interest(2) | [2] | (1,596) | |
Present value of minimum debt payments | 22,588 | ||
Less: current portion | (11,780) | ||
Noncurrent portion of debt | 10,808 | ||
Related Party Loan Payable [Member] | |||
2017 (remaining nine months) | 31,511 | ||
Debt Future Minimum Payments Due in Two Years | |||
2,019 | |||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments(1) | [1] | 31,511 | |
Less: amount representing interest(2) | [2] | (957) | |
Present value of minimum debt payments | 30,554 | ||
Less: current portion | (30,554) | ||
Noncurrent portion of debt | |||
Credit Facility [Member] | |||
2017 (remaining nine months) | 5,271 | ||
Debt Future Minimum Payments Due in Two Years | 33,710 | ||
2,019 | 2,580 | ||
2,020 | 2,500 | ||
2,021 | 27,396 | ||
Thereafter | |||
Total future minimum payments(1) | [1] | 71,457 | |
Less: amount representing interest(2) | [2] | (22,214) | |
Present value of minimum debt payments | 49,243 | ||
Less: current portion | (1,222) | ||
Noncurrent portion of debt | $ 48,021 | ||
[1] | Including $11.8 million in 2017 related to Nomis Bay convertible note which , at the Company's election, may be settled in shares or cash, be settled in shares and $46.8 million in 2018 and 2019 subject to Maturity Treatment Agreement, which will be converted to common stock at maturity, subject to there being no default under the terms of the debt. | ||
[2] | Including debt discount and issuance cost of $42.5 million associated with the related party and non-related party debt which will be accreted to interest expense under the effective interest method over the term of the debt. |
Note 6 - Commitments and Cont54
Note 6 - Commitments and Contingencies (Details Textual) BRL in Millions | 1 Months Ended | 3 Months Ended | |||||
Dec. 31, 2011BRL | Mar. 31, 2017USD ($) | Mar. 31, 2017BRL | Mar. 31, 2016USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2013USD ($) | Nov. 30, 2010 | |
Operating Leases, Rent Expense | $ 1,300,000 | $ 1,300,000 | |||||
Long-term Debt | 220,938,000 | $ 227,043,000 | |||||
Purchase Obligation | 3,700,000 | 800,000 | |||||
Contractual Obligation | 0 | 600,000 | |||||
Liabilities for Guarantees on Long-Duration Contracts, Guaranteed Benefit Liability, Net | 0 | $ 0 | |||||
Nossa Caixa and Banco Pine Agreements [Member] | |||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | 21,500,000 | BRL 68 | |||||
Related Party Convertible Notes [Member] | Unsecured Debt [Member] | |||||||
Debt Instrument, Face Amount | $ 69,000,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.50% | ||||||
Related Party Convertible Notes [Member] | Secured Debt [Member] | |||||||
Debt Instrument, Face Amount | $ 10,850,000 | ||||||
Purchase Obligation, Due in Second Year | $ 10,850,000 | ||||||
Replacement Notes [Member] | |||||||
Long-term Debt | $ 3,700,000 | ||||||
Manufacturing Agreement, Aprinnova JV [Member] | |||||||
Contractual Obligation | 10,000,000 | ||||||
FINEP Credit Facility [Member] | |||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | ||||||
FINEP Credit Facility [Member] | Chattel Mortgage [Member] | |||||||
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | 1,900,000 | 6 | |||||
BNDES Credit Facility [Member] | |||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | BRL 24.9 | 7,900,000 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 7.00% | ||||||
BNDES Credit Facility [Member] | BNDES [Member] | |||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | $ 7,900,000 | BRL 24.9 |
Note 6 - Commitments and Cont55
Note 6 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Capital leases 2017 (remaining nine months) | $ 734 | |
Operating leases 2017 (remaining nine months) | 5,194 | |
Total lease obligations 2017 (remaining nine months) | 5,928 | |
Capital leases 2018 | 106 | |
Operating leases 2018 | 6,909 | |
Total lease obligations 2018 | 7,015 | |
Capital leases 2019 | 9 | |
Operating leases 2019 | 6,782 | |
Total lease obligations 2019 | 6,791 | |
Capital leases 2020 | 0 | |
Operating leases 2020 | 7,012 | |
Total lease obligations 2020 | 7,012 | |
Capital leases 2021 | 0 | |
Operating leases 2021 | 7,248 | |
Total lease obligations 2021 | 7,248 | |
Capital leases thereafter | 0 | |
Operating leases thereafter | 10,993 | |
Total lease obligations thereafter | 10,993 | |
Total future minimum capital lease payments | 849 | |
Total future minimum operating lease payments | 44,138 | |
Total future minimum lease payments | 44,987 | |
Less: amount representing interest | (39) | |
Present value of minimum lease payments | 810 | |
Less: current portion | (405) | $ (922) |
Capital lease obligation, net of current portion | $ 405 | $ 334 |
Note 7 - Joint Ventures and N56
Note 7 - Joint Ventures and Noncontrolling Interest (Details Textual) | Dec. 19, 2016USD ($) | Dec. 05, 2016USD ($) | Feb. 12, 2016USD ($) | Feb. 12, 2016EUR (€) | Dec. 31, 2016USD ($)shares | Dec. 31, 2016BRLshares | Nov. 30, 2016USD ($)shares | Feb. 29, 2016USD ($) | Nov. 30, 2014USD ($) | Oct. 31, 2014USD ($) | Sep. 30, 2014USD ($) | Apr. 30, 2014USD ($) | Feb. 28, 2014 | Mar. 31, 2017USD ($) | Mar. 31, 2016USD ($) | Mar. 31, 2013USD ($) | Dec. 31, 2016USD ($) | Mar. 31, 2017EUR (€) | Dec. 31, 2016BRL | Jul. 19, 2016USD ($) | Dec. 31, 2015USD ($) | Oct. 14, 2015USD ($) | May 31, 2015USD ($) | Dec. 31, 2013USD ($) |
Operating Leases, Rent Expense | $ 1,300,000 | $ 1,300,000 | ||||||||||||||||||||||
Total [Member] | ||||||||||||||||||||||||
Extinguishment of Debt, Amount | € | € 50,000 | |||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | ||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 69,000,000 | |||||||||||||||||||||||
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | ||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 1,300,000 | |||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | ||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 3,700,000 | $ 3,700,000 | ||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | |||||||||||||||||||||||
Nikko Note [Member] | Nikko [Member] | ||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,900,000 | $ 3,900,000 | $ 3,900,000 | |||||||||||||||||||||
Novvi LLC [Member] | ||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 50.00% | 50.00% | ||||||||||||||||||||||
Initial Term of Joint Venture | 20 years | |||||||||||||||||||||||
IP License, Value | $ 10,000,000 | |||||||||||||||||||||||
Equity Method Investments | $ 0 | $ 0 | $ 0 | $ 0 | ||||||||||||||||||||
Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price | $ 600,000 | |||||||||||||||||||||||
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures | $ 2,100,000 | |||||||||||||||||||||||
Loan Granted to Joint Venture | $ 1,900,000 | $ 3,700,000 | $ 1,600,000 | $ 1,100,000 | ||||||||||||||||||||
Loan Granted to Joint Venture, Stated Annual Interest Rate | 0.36% | |||||||||||||||||||||||
Loan to Joint Venture, Percentage Provided by Each the Company and the Partner | 50.00% | 50.00% | ||||||||||||||||||||||
Loan Granted to Joint Venture, Amount Disbursed by Company | $ 1,000,000 | $ 1,800,000 | ||||||||||||||||||||||
Loan Granted to Joint Venture, Amount of First Installment Paid by Company | $ 1,200,000 | |||||||||||||||||||||||
Loan Granted to Joint Venture, Amount of Second Installment Paid by Company | $ 600,000 | |||||||||||||||||||||||
Novvi S.A. [Member] | ||||||||||||||||||||||||
Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price | $ 200,000 | |||||||||||||||||||||||
JVCO Joint Venture [Member] | ||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 25.00% | 25.00% | 25.00% | 25.00% | ||||||||||||||||||||
Capitalization, Long-term Debt and Equity | $ 100,000 | € 100,000 | ||||||||||||||||||||||
JVCO Joint Venture [Member] | Total [Member] | ||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage Exchanged for Cancellation of Debt | 25.00% | |||||||||||||||||||||||
Equity Method Investment, Ownership Percentage by Counterparty | 75.00% | 75.00% | ||||||||||||||||||||||
SMA Industria Quimica S.A. [Member] | ||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 100.00% | 50.00% | 100.00% | 100.00% | ||||||||||||||||||||
Initial Term of Joint Venture | 20 years | |||||||||||||||||||||||
Operation Commencement Timeline Requirement, Extension | 1 year 180 days | |||||||||||||||||||||||
Share Purchase and Sale Agreement Purchase Price of Shares | $ 15,780 | BRL 50,000 | ||||||||||||||||||||||
Share Purchase and Sale Agreement, Number of Shares Purchased | shares | 50,000 | 50,000 | ||||||||||||||||||||||
Operating Leases, Rent Expense | BRL 9,853 | $ 3,110 | ||||||||||||||||||||||
SMA Industria Quimica S.A. [Member] | SMSA [Member] | ||||||||||||||||||||||||
Due from Joint Ventures | $ 19,500,000 | $ 19,500,000 | BRL 61,800,000 | |||||||||||||||||||||
Glycotech and Salisbury [Member] | ||||||||||||||||||||||||
Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price | $ 4,350,000 | |||||||||||||||||||||||
Joint Venture, Aggregate Purchase Price, Promissory Note Consideration | $ 3,500,000 | |||||||||||||||||||||||
Neossance JV [Member] | ||||||||||||||||||||||||
Loan Granted to Joint Venture | $ 500,000 | |||||||||||||||||||||||
Cosan [Member] | Novvi LLC [Member] | ||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 50.00% | |||||||||||||||||||||||
Obligation to Fund Agreement, Cash Portion | $ 10,000,000 | |||||||||||||||||||||||
Joint Venture, Additional Membership Units Purchased, Aggregate Purchase Price | $ 600,000 | |||||||||||||||||||||||
Loan to Joint Venture, Percentage Provided by Each the Company and the Partner | 50.00% | 50.00% | 50.00% | 50.00% | ||||||||||||||||||||
American Refining Group [Member] | Novvi LLC [Member] | ||||||||||||||||||||||||
Obligation to Fund Agreement, Cash Portion | $ 10,000,000 | $ 10,000,000 | $ 10,000,000 | |||||||||||||||||||||
Chevron U.S.A. [Member] | Novvi LLC [Member] | ||||||||||||||||||||||||
Obligation to Fund Agreement, Cash Portion | $ 1,000,000 | |||||||||||||||||||||||
Joint Venture, Membership Units | shares | 20,000 | |||||||||||||||||||||||
Joint Venture, Ownership Stake | 3.00% | |||||||||||||||||||||||
Joint Venture, Additional Ownership Stake | 25.00% | |||||||||||||||||||||||
Nikko [Member] | Neossance JV [Member] | ||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 50.00% | |||||||||||||||||||||||
Loan Granted to Joint Venture | $ 1,500,000 | |||||||||||||||||||||||
Cash Investment Joint Venture | 10,000,000 | |||||||||||||||||||||||
Joint Venture, Maximum Distributions | $ 10,000,000 |
Note 7 - Joint Ventures and N57
Note 7 - Joint Ventures and Noncontrolling Interest - Variable Interest Entities (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Assets | $ 2,306 | $ 2,277 |
Liabilities | $ 158 | $ 135 |
Note 7 - Joint Ventures and N58
Note 7 - Joint Ventures and Noncontrolling Interest - Noncontrolling Interest (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Balance, noncontrolling interest | $ 937 | |
Balance, noncontrolling interest | 937 | |
Noncontrolling Interest [Member] | ||
Balance, noncontrolling interest | 937 | $ 391 |
Acquisition of noncontrolling interest | 0 | (277) |
Balance, noncontrolling interest | $ 937 | $ 114 |
Note 8 - Significant Agreemen59
Note 8 - Significant Agreements (Details Textual) $ / shares in Units, shares in Millions | Jan. 15, 2018USD ($) | Jan. 15, 2017USD ($) | Dec. 29, 2016USD ($) | Nov. 30, 2016USD ($) | Sep. 30, 2016 | Jul. 25, 2016USD ($) | Jun. 30, 2016USD ($)$ / sharesshares | Mar. 08, 2016USD ($) | Apr. 30, 2014USD ($) | Dec. 31, 2016USD ($) | Jun. 30, 2016USD ($)$ / sharesshares | Apr. 30, 2016 | Sep. 30, 2015USD ($) | Mar. 31, 2015USD ($) | Mar. 31, 2014USD ($) | Mar. 31, 2013USD ($) | Feb. 28, 2011 | Mar. 31, 2017USD ($)$ / shares | Mar. 31, 2016USD ($)$ / shares | Mar. 31, 2017USD ($)$ / shares | Mar. 31, 2017USD ($)$ / shares | Dec. 31, 2016USD ($) | Aug. 06, 2016$ / sharesshares |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | $ 10.67 | $ 0.01 | $ 0.01 | |||||||||||||||||||
At the Market Offering [Member] | |||||||||||||||||||||||
Common Stock, Value, Subscriptions | $ 50,000,000 | $ 50,000,000 | $ 50,000,000 | $ 50,000,000 | |||||||||||||||||||
Commission Rate | 3.00% | ||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | 0 | ||||||||||||||||||||||
Technology Investment Agreement with DARPA [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 4 years | ||||||||||||||||||||||
Revenue from Related Parties | 1,000,000 | $ 400,000 | |||||||||||||||||||||
Maximum DARPA Funding to be Received if all Milestones are Achieved | $ 35,000,000 | ||||||||||||||||||||||
Collective Obligation Due | $ 15,500,000 | ||||||||||||||||||||||
Firmenich [Member] | |||||||||||||||||||||||
Additional Grants and Collaboration Funding | 5,000,000 | ||||||||||||||||||||||
Firmenich [Member] | Collaborative Arrangement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 1,100,000 | 3,000,000 | |||||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 10 years | ||||||||||||||||||||||
Collaboration Agreement, Automatic Renewal Period | 3 years | ||||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term, Minimum | 12 years | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year One | $ 10,000,000 | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year Three | $ 10,000,000 | ||||||||||||||||||||||
Collaboration Agreement Annual Funding Year Two | $ 10,000,000 | ||||||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | Master Collaboration Agreement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 1,200,000 | 2,000,000 | |||||||||||||||||||||
Sales Margin Company Percentage Split | 30.00% | ||||||||||||||||||||||
Return Required for Collaboration Partner Before Adjusting Split on Sales Margin | $ 15,000,000 | ||||||||||||||||||||||
Sales Margin Company Percentage Split Following Return Requirements | 50.00% | ||||||||||||||||||||||
Success Bonus | $ 2,500,000 | ||||||||||||||||||||||
Sales Margin Collaborator Percentage Split | 70.00% | ||||||||||||||||||||||
Sales Margin Collaborator Percentage Split Following Return Requirements | 30.00% | ||||||||||||||||||||||
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | Amended Collaboration Agreement [Member] | |||||||||||||||||||||||
Royalty Rate, Percent of Net Revenue | 10.00% | ||||||||||||||||||||||
Kuraray [Member] | Collaborative Arrangement [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 2 years | ||||||||||||||||||||||
Revenue from Related Parties | 100,000 | 400,000 | |||||||||||||||||||||
Proceeds from Collaborators | $ 500,000 | $ 2,000,000 | $ 2,000,000 | $ 4,000,000 | |||||||||||||||||||
Collaborative Agreement Number Of Installments | 2 | 2 | |||||||||||||||||||||
Deferred Revenue | $ 1,000,000 | ||||||||||||||||||||||
Kuraray [Member] | Collaborative Arrangement [Member] | Scenario, Forecast [Member] | |||||||||||||||||||||||
Proceeds from Collaborators | $ 500,000 | ||||||||||||||||||||||
Kuraray [Member] | Product Sales [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 1,600,000 | 0 | |||||||||||||||||||||
Nenter & Co., Inc. [Member] | Supply Agreements [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 2,300,000 | ||||||||||||||||||||||
Supply Agreement, Renewable Terms | 5 years | ||||||||||||||||||||||
Givaudan International, SA [Member] | Collaborative Arrangement [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 5 years | ||||||||||||||||||||||
Collaboration Agreement, Automatic Renewal Period | 2 years | ||||||||||||||||||||||
Revenue from Related Parties | 1,500,000 | ||||||||||||||||||||||
Collaboration Agreement, Maxium Number of Extension Renewals | 3 | ||||||||||||||||||||||
Semi Annual Installments, Amount | $ 3,000,000 | ||||||||||||||||||||||
Givaudan International, SA [Member] | Collaborative Arrangement [Member] | Deferred Revenue [Member] | |||||||||||||||||||||||
Proceeds from Collaborators | $ 3,000,000 | $ 3,000,000 | |||||||||||||||||||||
Givaudan International, SA [Member] | Collaborative Arrangement [Member] | Scenario, Forecast [Member] | |||||||||||||||||||||||
Proceeds from Collaborators | 12,000,000 | ||||||||||||||||||||||
Givaudan International, SA [Member] | Supply Agreements [Member] | |||||||||||||||||||||||
Revenue from Related Parties | 600,000 | $ 0 | |||||||||||||||||||||
Ginkgo Bioworks [Member] | |||||||||||||||||||||||
Collaboration Agreement Period | 3 years | ||||||||||||||||||||||
Collaboration Agreement, Automatic Renewal Period | 1 year | ||||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term, Minimum | 90 days | ||||||||||||||||||||||
Proceeds from Collaborators | $ 15,000,000 | $ 20,000,000 | |||||||||||||||||||||
Royalty Percentage | 10.00% | 10.00% | |||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue | shares | 5 | 5 | |||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue, Exercise Price Per Share | $ / shares | $ 0.50 | $ 0.50 | |||||||||||||||||||||
Collaboration Agreement, Common Stock Options Agreed to Issue, Term Exercisable from Date of Issuance | 1 year | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 5 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.50 | ||||||||||||||||||||||
Collaborative Agreement, Notice Requirement before Terminating Current Term Due to Lack of Commitment | 30 days | ||||||||||||||||||||||
Ginkgo Bioworks [Member] | Scenario, Forecast [Member] | |||||||||||||||||||||||
Proceeds from Collaborators | 5,000,000 | 5,000,000 | |||||||||||||||||||||
Collaborative Agreement Number Of Installments | 2 | ||||||||||||||||||||||
Ginkgo Bioworks [Member] | Ginkgo Collaboration Agreement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | $ 0 | ||||||||||||||||||||||
Due to Related Parties | $ 1,600,000 | $ 3,000,000 | $ 3,000,000 | $ 3,000,000 | $ 1,600,000 | ||||||||||||||||||
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | |||||||||||||||||||||||
Revenue from Related Parties | $ 10,000,000 |
Note 9 - Goodwill and Intangi60
Note 9 - Goodwill and Intangible Assets (Details Textual) $ in Millions | 1 Months Ended |
Oct. 31, 2011USD ($) | |
Draths Corporation [Member] | In Process Research and Development, Indefinite [Member] | |
Indefinite-lived Intangible Assets Acquired | $ 8.6 |
Note 9 - Goodwill and Intangi61
Note 9 - Goodwill and Intangible Assets - Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2017 | Dec. 31, 2016 | |
Goodwill, carrying amount | $ 560 | $ 560 |
Goodwill, net carrying value | 560 | 560 |
Goodwill and intangible assets, gross | 9,892 | 9,892 |
Intangible assets impairment and accumulated amortization | (9,332) | (9,332) |
Goodwill and intangible assets, net | 560 | 560 |
Acquired Licenses and Permits [Member] | ||
Intangible assets, gross | $ 772 | 772 |
Acquired licenses and permits, useful life (Year) | 2 years | |
Accumulated amortization of intangible assets | $ (772) | (772) |
In Process Research and Development, Indefinite [Member] | ||
Intangible assets, gross | 8,560 | 8,560 |
Impairment of intangible assets | (8,560) | (8,560) |
Intangible assets, net |
Note 10 - Stockholders' Defic62
Note 10 - Stockholders' Deficit (Details Textual) - $ / shares | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Class of Warrant or Right, Outstanding | 14,663,411 | 7,328,069 |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | $ 10.67 |
Class of Warrant or Right, Term | 5 years 36 days |
Note 11 - Stock-based Compens63
Note 11 - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 0 | $ 0 |
Employee Stock Option [Member] | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 3,700 | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 259 days | |
Restricted Stock Units (RSUs) [Member] | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 4,700 | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 211 days |
Note 11 - Stock-based Compens64
Note 11 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2017 | |
Outstanding (in shares) | 13,487,685 | ||
Outstanding, weighted average exercise price (in dollars per share) | $ 3.63 | ||
Outstanding, weighted average remaining contractual life (Year) | 6 years 302 days | 6 years 255 days | |
Outstanding, aggregate intrinsic value | $ 443 | ||
Options granted (in shares) | 726,000 | ||
Options granted, weighted average exercise price (in dollars per share) | $ 0.58 | ||
Options exercised (in shares) | (500) | ||
Options exercised, weighted average exercise price (in dollars per share) | $ 0.28 | ||
Options cancelled (in shares) | (695,912) | ||
Options cancelled, weighted average exercise price (in dollars per share) | $ 1.82 | ||
Outstanding (in shares) | 13,517,273 | 13,487,685 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 3.55 | $ 3.63 | |
Outstanding, aggregate intrinsic value | $ 443 | $ 443 | $ 44 |
Vested and expected to vest after March 31, 2017 (in shares) | 12,347,493 | ||
Vested and expected to vest after December 31, 2016, weighted average exercise price (in dollars per share) | $ 3.79 | ||
Vested and expected to vest after December 31, 2016, weighted average remaining contractual life (Year) | 6 years 229 days | ||
Vested and expected to vest after December 31, 2016, aggregate intrinsic value | $ 38 | ||
Exercisable at March 31, 2017 (in shares) | 7,478,686 | ||
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 5.42 | ||
Exercisable at December 31, 2016, weighted average remaining contractual life (Year) | 5 years 102 days | ||
Exercisable at December 31, 2016, aggregate intrinsic value | $ 1 |
Note 11 - Stock-based Compens65
Note 11 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2017 | Dec. 31, 2016 | |
Outstanding, RSUs (in shares) | 6,997,084 | |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 1.18 | |
Outstanding, weighted average remaining contractual life (Year) | 1 year 142 days | 1 year 160 days |
Awarded (in shares) | 825,980 | |
Awarded (in dollars per share) | $ 0.59 | |
Vested (in shares) | (348,699) | |
Vested (in dollars per share) | $ 1.28 | |
Forfeited (in shares) | (250,329) | |
Forfeited (in dollars per share) | $ 1.03 | |
Outstanding, RSUs (in shares) | 7,224,036 | 6,997,084 |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ 1.11 | $ 1.18 |
Expected to vest after March 31, 2017 (in shares) | 5,735,089 | |
Expected to vest after December 31, 2016, weighted average grant-date fair value (in dollars per share) | $ 1.15 | |
Expected to vest after December 31, 2016, weighted average remaining contractual life (Year) | 1 year 62 days |
Note 11 - Share-based Compensat
Note 11 - Share-based Compensation - Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details) | 3 Months Ended |
Mar. 31, 2017$ / sharesshares | |
Exercise Price, Lower (in dollars per share) | $ 0.28 |
Exercise Price, Upper (in dollars per share) | $ 30.17 |
Options Outstanding Number (in shares) | shares | 13,517,273 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 6 years 302 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 3.55 |
Options Exercisable Number Options (in shares) | shares | 7,478,686 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 5.42 |
Exercise Price Range 1 [Member] | |
Exercise Price, Lower (in dollars per share) | 0.28 |
Exercise Price, Upper (in dollars per share) | $ 0.58 |
Options Outstanding Number (in shares) | shares | 795,734 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 9 years 175 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 0.49 |
Options Exercisable Number Options (in shares) | shares | 2,234 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 0.28 |
Exercise Price Range 2 [Member] | |
Exercise Price, Lower (in dollars per share) | 0.59 |
Exercise Price, Upper (in dollars per share) | $ 0.59 |
Options Outstanding Number (in shares) | shares | 2,224,375 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 9 years 47 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 0.59 |
Options Exercisable Number Options (in shares) | shares | |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | |
Exercise Price Range 3 [Member] | |
Exercise Price, Lower (in dollars per share) | 0.69 |
Exercise Price, Upper (in dollars per share) | $ 1.63 |
Options Outstanding Number (in shares) | shares | 1,491,082 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 8 years 244 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 1.30 |
Options Exercisable Number Options (in shares) | shares | 361,067 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 1.60 |
Exercise Price Range 4 [Member] | |
Exercise Price, Lower (in dollars per share) | 1.64 |
Exercise Price, Upper (in dollars per share) | $ 1.96 |
Options Outstanding Number (in shares) | shares | 2,192,975 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 7 years 186 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 1.84 |
Options Exercisable Number Options (in shares) | shares | 1,026,492 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 1.83 |
Exercise Price Range 5 [Member] | |
Exercise Price, Lower (in dollars per share) | 1.98 |
Exercise Price, Upper (in dollars per share) | $ 2.87 |
Options Outstanding Number (in shares) | shares | 1,780,408 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 6 years 25 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 2.69 |
Options Exercisable Number Options (in shares) | shares | 1,579,154 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 2.73 |
Exercise Price Range 6 [Member] | |
Exercise Price, Lower (in dollars per share) | 2.96 |
Exercise Price, Upper (in dollars per share) | $ 3.44 |
Options Outstanding Number (in shares) | shares | 688,795 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 6 years 146 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 3.15 |
Options Exercisable Number Options (in shares) | shares | 597,154 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 3.13 |
Exercise Price Range 7 [Member] | |
Exercise Price, Lower (in dollars per share) | 3.51 |
Exercise Price, Upper (in dollars per share) | $ 3.51 |
Options Outstanding Number (in shares) | shares | 1,447,979 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 6 years 328 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 3.51 |
Options Exercisable Number Options (in shares) | shares | 1,057,049 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 3.51 |
Exercise Price Range 8 [Member] | |
Exercise Price, Lower (in dollars per share) | 3.55 |
Exercise Price, Upper (in dollars per share) | $ 4.31 |
Options Outstanding Number (in shares) | shares | 1,723,976 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 3 years 113 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 3.97 |
Options Exercisable Number Options (in shares) | shares | 1,683,443 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 3.98 |
Exercise Price Range 9 [Member] | |
Exercise Price, Lower (in dollars per share) | 4.35 |
Exercise Price, Upper (in dollars per share) | $ 26.84 |
Options Outstanding Number (in shares) | shares | 1,111,949 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 3 years 189 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 17.71 |
Options Exercisable Number Options (in shares) | shares | 1,111,949 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 17.71 |
Exercise Price Range 10 [Member] | |
Exercise Price, Lower (in dollars per share) | 30.17 |
Exercise Price, Upper (in dollars per share) | $ 30.17 |
Options Outstanding Number (in shares) | shares | 60,000 |
Options Outstanding Weighted- Average Remaining Contractual Life (Year) | 3 years 350 days |
Options Outstanding Weighted-Average Exercise Price (in dollars per share) | $ 30.17 |
Options Exercisable Number Options (in shares) | shares | 60,000 |
Options Exercisable Weighted-Average Exercise Price (in dollars per share) | $ 30.17 |
Note 11 - Stock-based Compens67
Note 11 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Allocated share-based compensation expense | $ 1,646 | $ 2,051 |
Research and Development Expense [Member] | ||
Allocated share-based compensation expense | 484 | 491 |
Selling, General and Administrative Expenses [Member] | ||
Allocated share-based compensation expense | $ 1,162 | $ 1,560 |
Note 11 - Stock-based Compens68
Note 11 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member] | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Risk-free interest rate | 2.10% | 1.40% |
Expected term (in years) (Year) | 6 years 54 days | 6 years 83 days |
Expected volatility | 80.00% | 73.00% |
Note 12 - Employee Benefit Pl69
Note 12 - Employee Benefit Plan (Details Textual) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 90.00% | |
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 90.00% | |
Defined Contribution Plan, Minimum Service, Vesting Period | 1 year | |
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 0.1 | $ 0.1 |
Note 13 - Related Party Trans70
Note 13 - Related Party Transactions (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | ||||
Jul. 31, 2015 | May 31, 2014 | Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2015 | Dec. 31, 2016 | |
Debt Instrument, Unamortized Discount | $ 42,000,000 | |||||
Accounts Receivable, Related Parties | 416,000 | $ 872,000 | ||||
Related Party Convertible Notes [Member] | ||||||
Convertible Debt | 73,900,000 | 72,400,000 | ||||
Debt Instrument, Unamortized Discount | 6,000,000 | 6,700,000 | ||||
Derivative Liability | 1,400,000 | 800,000 | ||||
Derivative, Gain (Loss) on Derivative, Net | 1,100,000 | $ 4,500,000 | ||||
Total [Member] | ||||||
Convertible Debt | $ 5,000,000 | |||||
Accounts Receivable, Related Parties | 300,000 | 800,000 | ||||
Revenue from Related Parties | 0 | 0 | ||||
Total [Member] | Pilot Plant Agreements [Member] | ||||||
Related Party Agreement Term | 5 years | |||||
Related Party Transaction, Amounts of Transaction | 28,000,000 | |||||
Related Party Transaction, Fees Waived | $ 2,000,000 | |||||
Due to Related Parties | 1,700,000 | $ 2,200,000 | ||||
Total [Member] | Pilot Plant Agreements [Member] | Sublease Agreement [Member] | ||||||
Related Party Transaction, Amounts of Transaction | $ 0 | $ 200,000 | ||||
Proceeds from Fees Received | $ 1,700,000 | |||||
Total [Member] | Pilot Plant Agreements [Member] | Scale-up Services and Training [Member] | ||||||
Related Party Transaction, Amounts of Transaction | $ 900,000 |
Note 14 - Income Taxes (Details
Note 14 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Income Tax Expense (Benefit) | $ (41) | $ 115 |
Note 15 - Reporting Segments (D
Note 15 - Reporting Segments (Details Textual) | 3 Months Ended |
Mar. 31, 2017 | |
Segment Reporting, Number Of Business Activities | 1 |
Number of Operating Segments | 1 |
Number of Reporting Units | 1 |
Note 15 - Reporting Segments -
Note 15 - Reporting Segments - Revenues by Geography (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Revenues | $ 12,980 | $ 8,811 |
Europe [Member] | ||
Revenues | 5,376 | 4,372 |
UNITED STATES | ||
Revenues | 3,096 | 3,462 |
Asia [Member] | ||
Revenues | 4,433 | 590 |
BRAZIL | ||
Revenues | 19 | 375 |
Other Area [Member] | ||
Revenues | $ 56 | $ 12 |
Note 15 - Reporting Segments 74
Note 15 - Reporting Segments - Long-lived Assets by Geography (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Long-Lived Assets | $ 53,045 | $ 53,735 |
BRAZIL | ||
Long-Lived Assets | 39,137 | 44,153 |
UNITED STATES | ||
Long-Lived Assets | 13,683 | 9,342 |
Europe [Member] | ||
Long-Lived Assets | $ 225 | $ 240 |
Note 16 - Comprehensive Loss -
Note 16 - Comprehensive Loss - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands | Mar. 31, 2017 | Dec. 31, 2016 |
Foreign currency translation adjustment, net of tax | $ (40,581) | $ (40,904) |
Total accumulated other comprehensive loss | $ (40,581) | $ (40,904) |
Note 17 - Net Loss Attributab76
Note 17 - Net Loss Attributable to Common Stockholders and Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Net loss attributable to Amyris, Inc. common stockholders | $ (37,371) | $ (15,308) |
Interest on convertible debt | 1,817 | |
Accretion of debt discount | 1,633 | |
Gain from change in fair value of derivative instruments | (18,415) | |
Net loss attributable to Amyris, Inc. common stockholders after assumed conversion | $ (37,371) | $ (30,273) |
Basic (in shares) | 290,039,216 | 207,199,563 |
Basic and diluted loss per share (in dollars per share) | $ (0.13) | $ (0.07) |
Convertible promissory notes (in shares) | 53,732,522 | |
Weighted common stock equivalents (in shares) | 53,732,522 | |
Diluted weighted-average common shares (in shares) | 290,039,216 | 260,932.09 |
Diluted (in dollars per share) | $ (0.13) | $ (0.12) |
Note 17 - Net Loss Attributab77
Note 17 - Net Loss Attributable to Common Stockholders and Net Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares | 3 Months Ended | ||
Mar. 31, 2017 | Mar. 31, 2016 | ||
Antidilutive securities (in shares) | 98,588,504 | 122,869,085 | |
Stock Options to Purchase Common Stock [Member] | |||
Antidilutive securities (in shares) | 13,517,273 | 12,159,154 | |
Convertible Promissory Notes [Member] | |||
Antidilutive securities (in shares) | [1] | 72,826,108 | 99,648,739 |
Common Stock Subject to Repurchase [Member] | |||
Antidilutive securities (in shares) | 5,021,087 | 5,885,762 | |
Restricted Stock Units (RSUs) [Member] | |||
Antidilutive securities (in shares) | 7,224,036 | 5,175,430 | |
[1] | The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 18 - Subsequent Events (De
Note 18 - Subsequent Events (Details Textual) | May 23, 2017 | May 11, 2017USD ($)$ / sharesshares | May 08, 2017USD ($)$ / sharesshares | Apr. 30, 2017 | Apr. 21, 2017shares | Apr. 13, 2017USD ($)$ / sharesshares | Jun. 22, 2017USD ($) | Dec. 31, 2017USD ($) | May 02, 2017 | May 01, 2017 | Apr. 17, 2017USD ($) | Mar. 31, 2017USD ($)$ / shares | Dec. 31, 2016USD ($)$ / shares | Mar. 31, 2016$ / shares |
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | ||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | 0.0001 | $ 0.0001 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | $ 10.67 | ||||||||||||
Long-term Debt | $ 220,938,000 | $ 227,043,000 | ||||||||||||
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | ||||||||||||||
Accounts Receivable, Gross | 10,000,000 | |||||||||||||
Scenario, Forecast [Member] | Reverse Stock Split [Member] | ||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 | |||||||||||||
Scenario, Forecast [Member] | Nenter & Co., Inc. [Member] | ||||||||||||||
Loss on Contract Termination | $ 2,500,000 | |||||||||||||
Convertible Debt [Member] | ||||||||||||||
Long-term Debt | 75,218,000 | $ 78,981,000 | ||||||||||||
Convertible Debt [Member] | Temasek [Member] | ||||||||||||||
Long-term Debt | $ 10,000,000 | |||||||||||||
Subsequent Event [Member] | ||||||||||||||
Extinguishment of Debt, Amount | $ 40,200,000 | |||||||||||||
Voting Agreement Aggregate Ownership Percentage | 51.20% | |||||||||||||
Subsequent Event [Member] | Foris Ventures, LLC [Member] | ||||||||||||||
Debt Conversion, Original Debt, Amount | $ 27,000,000 | |||||||||||||
Subsequent Event [Member] | Naxyris S.A. [Member] | ||||||||||||||
Debt Conversion, Original Debt, Amount | $ 2,000,000 | |||||||||||||
Subsequent Event [Member] | Foris and Naxyris [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member] | ||||||||||||||
Conversion of Stock, Shares Converted | shares | 20,920,578 | |||||||||||||
Subsequent Event [Member] | May 2017 Offering Closing [Member] | ||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 44,500,000 | |||||||||||||
Subsequent Event [Member] | May 2017 Warrants [Member] | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 207,954,414 | |||||||||||||
Subsequent Event [Member] | May 2017 Warrants, Warrant 1 [Member] | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 103,977,207 | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.52 | |||||||||||||
Class of Warrant or Right, Common Stock Available for Conversion, Percentage | 50.00% | |||||||||||||
Subsequent Event [Member] | May 2017 Warrants, Warrant 2 [Member] | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 103,977,207 | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.62 | |||||||||||||
Class of Warrant or Right, Common Stock Available for Conversion, Percentage | 50.00% | |||||||||||||
Subsequent Event [Member] | Dilution Warrants [Member] | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.0001 | |||||||||||||
Preferred Stock Effective Conversion Price | $ / shares | $ 0.42 | |||||||||||||
Subsequent Event [Member] | Series A Preferred Stock [Member] | ||||||||||||||
Preferred Stock, Capital Shares Reserved for Future Issuance | shares | 22,140 | |||||||||||||
Preferred Stock, Dividend Rate, Percentage | 17.38% | |||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | |||||||||||||
Preferred Stock, Stated Value | $ / shares | 1,000 | |||||||||||||
Preferred Stock, Conversion Price Per Share to Common Stock | $ / shares | 1.15 | |||||||||||||
Preferred Stock, Anniversary Payment | $ / shares | $ 1,738 | |||||||||||||
Subsequent Event [Member] | Series B Preferred Stock [Member] | ||||||||||||||
Preferred Stock, Capital Shares Reserved for Future Issuance | shares | 65,203.8756 | |||||||||||||
Preferred Stock, Dividend Rate, Percentage | 17.38% | |||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | |||||||||||||
Subsequent Event [Member] | Series B Preferred Stock [Member] | Foris Ventures, LLC [Member] | ||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 30,728.589 | |||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares | 73,160,764 | |||||||||||||
Subsequent Event [Member] | Series B Preferred Stock [Member] | Naxyris S.A. [Member] | ||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 2,333.216 | |||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares | 5,556,038 | |||||||||||||
Subsequent Event [Member] | Series A Preferred Stock and Warrants [Member] | May 2017 Offering Closing [Member] | ||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 22,140,000 | |||||||||||||
Subsequent Event [Member] | Series B Preferred Stock and Warrants [Member] | May 2017 Offering Closing [Member] | ||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 25,000,000 | |||||||||||||
Subsequent Event [Member] | Series C Preferred Stock [Member] | ||||||||||||||
Preferred Stock, Stated Value | $ / shares | $ 1,000 | |||||||||||||
Subsequent Event [Member] | Series C Preferred Stock [Member] | Reverse Stock Split [Member] | ||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 1 | |||||||||||||
Subsequent Event [Member] | Series C Preferred Stock [Member] | Foris and Naxyris [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member] | ||||||||||||||
Conversion of Stock, Shares Issued | shares | 20,920.578 | |||||||||||||
Subsequent Event [Member] | Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | SweeGen Common Stock [Member] | ||||||||||||||
Shares Received in Satisfaction of Payment Obligation | shares | 850,115 | |||||||||||||
Subsequent Event [Member] | DSM International B.V. [Member] | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 59,521,740 | |||||||||||||
Proceeds from Issuance of Private Placement | $ 25,000,000 | |||||||||||||
Ownership Percentage, Designated Director Threshold | 4.50% | |||||||||||||
Sale of Stock, Percentage of Shares Available for Issuance | 25.00% | |||||||||||||
Second Tranche Closing, Anniversary Payment | $ 5,000,000 | |||||||||||||
Subsequent Event [Member] | DSM International B.V. [Member] | Series B Preferred Stock [Member] | ||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 25,000 | |||||||||||||
Subsequent Event [Member] | Foris and Naxyris [Member] | Series C Preferred Stock [Member] | ||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | |||||||||||||
Subsequent Event [Member] | Maximum [Member] | Series A Preferred Stock [Member] | ||||||||||||||
Beneficiary Ownership, Conversion Percentage, Maximum | 9.99% | |||||||||||||
Subsequent Event [Member] | Maximum [Member] | DSM International B.V. [Member] | ||||||||||||||
Designated Holder Maximum Common Stock Ownership | 33.00% | |||||||||||||
Reserved Second Tranche Securities | $ 30,000,000 | |||||||||||||
Subsequent Event [Member] | Minimum [Member] | Series A Preferred Stock [Member] | ||||||||||||||
Beneficiary Ownership, Conversion Percentage, Maximum | 4.99% | |||||||||||||
Subsequent Event [Member] | Minimum [Member] | DSM International B.V. [Member] | ||||||||||||||
Reserved Second Tranche Securities | $ 25,000,000 | |||||||||||||
Ginkgo Collaboration Note [Member] | Subsequent Event [Member] | ||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | |||||||||||||
The April 2017 Convertible Notes [Member] | Subsequent Event [Member] | Convertible Debt [Member] | ||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 1.90 | |||||||||||||
Debt Instrument, Redemption Price, Percentage | 118.00% | |||||||||||||
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount | 50.00% | |||||||||||||
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock | $ 200,000 | |||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions | 4.99% | |||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions | 9.99% | |||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice | 61 days | |||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum | shares | 54,676,770 | |||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Minimum | shares | 49,233,710 | |||||||||||||
Convertible Debt, Holder Limitations, Maximum Sale Price Per Share of Common Stock | $ / shares | $ 1.05 | |||||||||||||
Convertible Debt, Holders May Not Sell Shares, Price Floor, Threshold | $ / shares | $ 1 | |||||||||||||
The April 2017 Convertible Notes [Member] | Subsequent Event [Member] | Convertible Debt [Member] | Maximum [Member] | ||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | |||||||||||||
The April 2017 Convertible Notes, Initial Closing [Member] | Subsequent Event [Member] | Convertible Debt [Member] | ||||||||||||||
Debt Instrument, Face Amount | $ 7,000,000 | |||||||||||||
The April 2017 Convertible Notes, Second Closing [Member] | Convertible Debt [Member] | Scenario, Forecast [Member] | ||||||||||||||
Debt Instrument, Face Amount | $ 8,000,000 | |||||||||||||
The Amended Notes [Member] | Subsequent Event [Member] | ||||||||||||||
Convertible Debt Securities, Monthly Installment Discount | 20.00% | 10.00% | ||||||||||||
Convertible Debt Securities, Price Floor Payment Discount Rate | 70.00% | 80.00% | ||||||||||||
March 2014 Letter Agreement [Member] | Subsequent Event [Member] | ||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,400,000 | |||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | Subsequent Event [Member] | ||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,700,000 |